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A serological survey was performed using 165 human serum samples 
collected in Liberia. These sera were tested against selected arbo¬ 
viruses and other vertebrate viruses. By complement-fixation (CF) 
test 5 positives for Lassa Fever virus were found; three of these were 
previously documented during the 1972 outbreak at Zorzor, Liberia. 
Complement-fixation and hemagglutination-inhibition (HI) antibodies 
against chikungunya were found in 21% of specimens; neutralization 
tests correlated well with CF and HI test results. CF tests for Bwamba 
virus were positive in 7% or 5 specimens; neutralization tests confirmed 
most of these positives. HI tests were done with four group B antigens: 
dengue II, West Nile, yellow fever, and Zika. Of these four agents, 
neutralization tests were done only against Zika virus. Sera which demon¬ 
strated HI patterns of Zika primary infection, successfully neutralized 
Zika virus. Thus there is good evidence for the existence in Liberia of 
Zika virus. No conclusions could be drawn about the presence in Liberia 
of Ilesha or Bunyamwera, because of the poor correlation between HI tests 
and neutralization tests. Serological test results were negative against 
Congo virus by CF test and against Mokola virus by CF test. A few sera 
were weakly positive against Ingwavuma by HI test, but these sera failed 




The past quarter century has witnessed the isolation of a large 
number of previously unknown viruses from arthropods and vertebrates. 
Of the 359 viruses in the 1975 edition of the International Catalogue 
of Arboviruses Including Certain Other Viruses of Vertebrates, only 35 
were isolated during the first half of this century; the other 90% 
1 
were discovered after 1950. For each virus many questions need to be 
answered—the range of vectors and vertebrate hosts, the geographical 
distribution, and the potential for human infection and disease. In 
the region of West Africa, where a large number of arboviruses and 
other viruses has been isolated, these questions remain significantly 
unanswered for many viruses. This is especially true in countries 
without a virus research laboratory. 
In one such country, Liberia, virus studies have been quite limited 
during the past quarter century. In a 1970 review by Bres of serological 
studies on arboviruses in Africa, there is reference to only two Liberian 
2 
studies, both of which are unpublished. One study by the Rockefeller 
Foundation Virus Laboratory analyzed 101 human sera from five cities and 
towns in western Liberia—Monrovia, Zorzor, Balahum, Voinjama, and Ghanta. 
Data suggested that infections with group A, group B, and Bunyamwera group 
viruses were common in Liberia. The second study was done in 1967 by Robin 
on 388 sera from Loffa County, in response to a yellow fever outbreak in 
the town of Salayea in which there were 5 survivors and 3 deaths. Yellow 
fever antibodies were found in: none of 19 sera in the age range 0-4 years; 
none of 153 sera in the age range 5-14 years; 2 of 65 sera (3%) in the age 
range 15-24 years; and 20 of 137 sera (14.5%) in the age range 25-59 years. 
As in the Rockefeller Foundation survey, antibodies were found to group A, 
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group B, and Bunyarawera group viruses. 
One final study in Liberia consisted of an investigation in 1972 of 
a Lassa Fever outbreak at Curran Lutheran Hospital in the town of Zorzor 
in Loffa County. The outbreak involved 11 cases, of which 4 were fatal, 
giving a mortality rate of 36%. Lassa Fever virus is known to exist in 
several other West African countries, including Nigeria, where the first 
isolation was made in 1969 from humans, and also Sierra Leone. The 
ability of this virus to kill a high percentage of those infected, as 
demonstrated by outbreaks in each of these countries, makes further 
knowledge about this virus extremely desirable. 
Thus one objective of the present survey in Liberia is to help ascer¬ 
tain how widespread the antibodies to Lassa Fever virus might be, especially 
among hospital workers for whom there may be an increased risk of exposure. 
Two other viral agents in the present survey have also been isolated from 
fatal human infections. One of these, Mokola, is a rabies-related virus 
which has been isolated from two children in Nigeria, one of whom died of a 
3 
poliomyelitis-like illness. The second, Congo, has been isolated from 
humans in the Congo and Uganda. No human infections or human antibodies 
have been demonstrated in West Africa, although animals have demonstrated 
4 
the virus. As in previous studies of Liberia, group A, group B, and Buny- 
amwera group viruses have been included in the present survey; viruses from 
several other groups have also been included. 
Liberia lies on the west coast of Africa several degrees above the 
equator. Its area of 43,000 sq mi is about the size of Pennsylvania. There 
are three geographic zones: a 30-50 mile-wide strip of lowland along the 35 mi 
coast, characterized by mangrove marshes, lagoons, and tital creeks; an interior 
tropical rain forest extending all the way to the inland border and characterized 
by hills and plateaus rising to elevations of 600-1000 feet; the Guinea Highland 
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in the far northern part of Liberia, where the forest is sparce and 
mountains rise to 5000 ft. The climate is hot and humid with temper¬ 
atures in the 70*s and 80's. There is a dry season and rainy season. 
5 
Rainfall averages 175 in/yr along the coast and 75-100 in/yr inland. 
A 1971 survey estimated the population at 1,570,000. Seventy- 
two percent lived in rural areas (areas of 2,000 people or less), and 
6 
28 percent lived in urban areas. Large sections in the southeast 
third of Liberia and in the West in Loffa County are almost uninhabited. 
Population groups consist of 28 tribes, each with its own language,and 
also 15,000 descendants from black immigrants from the United States. 
The median age is 18.9 years, and the overall age distribution is 
typical of countries with high fertility and with a high proportion of 
young people. The general fertility rate (the annual number of live 
births per 1,000 women age 15-44 years) is 203. Agriculture is the main 
occupation for 3 out of 4 Liberians. Chief income for Liberia is derived 
from exports of iron ore and natural rubber. 
Chief causes of morbidity and mortality include malnutrition, 
malaria, helminthic infestations, diarrhea, dysentery, tuberculosis, 
schistosomiasis, and leprosy. Trypanosomiasis has not been noted to be a 
significant problem. Cholera has occurred in recent years. Leading causes 
of childhood morbidity and mortality are prematurity, malnutrition, pneu¬ 
monia and other respiratory infections, gastrointestinal infections, 
malaria, tetanus, measles, meningitis, and hepatitis. Overall statistics 
on morbidity and mortality are not readily available. However in 1970 it 
was estimated that 43% of all deaths were in children under one year of age. 
It was also estimated that 8 of 10 Liberians die at home, unattended by 
7 




Materials and Methods 
Section One: Serum Collection and Survey Questions 
Collections were made in Liberia from October through December, 
1974 at four sites: ELWA Hospital ( 12 miles outside Monrovia), 
Maternity Center (Monrovia), Phebe Hospital (approx. 80 miles NE of 
Monrovia), and Curran Hospital at Zorzor (about 130 miles NNE of 
Monrovia). Thus an effort was made to collect samples from several 
separate locations in Liberia. Criteria for selection of people to 
bleed included a preference for hospital workers in order to answer 
questions about nosocomial viral infections. However an effort was 
also made to obtain blood from those not working in hospitals, but 
who lived in the region served by the hospital. Essentially all of 
the people in this latter category were hospital inpatients, admitted 
with various problems including obstetrical, surgical, or medical 
problems. All of the hospital personnel were in good health. Very 
few of the inpatients in the survey had febrile illnesses suggestive 
of an ongoing infectious process. Permission for venipuncture was 
granted by almost all hospital personnel. Blood samples from hospital 
inpatients were obtained along with the routine lab work. Consent for 
venipuncture in the outpatient clinic or in villages was extremely 
difficult to obtain, and sample collections were not pursued in these 
settings. 
Blood was collected in 15cc vacutainer tubes via venipuncture of 
an alcohol-swabbed area. The tubes then stood upright at room tempera¬ 
ture for 8-12 hours, and then the clot was removed with a sterile ap- 
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plicator stick. Remaining blood cells were removed by centrifugation 
for 10 min at about 1000 rpm, followed by removal of the supernatant 
serum with a sterile Pasteur pipette. By this time the serum was 
reasonably clean, with very few specimens showing any trace of hemolysis 
and none with any red blood cells visible. The sera which averaged 4-5cc 
were stored in sterile plastic screw-capped tubes inside a household 
freezer. At the end of December the 165 samples were placed in styrofoam- 
insulated boxes, driven to Robertsfield International Airport and stored 
in a freezer. They were subsequently flown via Pan American Airlines to 
J.F.K. Airport, stored in a freezer until customs clearance, and then 
shipped to the Yale Arbovirus Research Unit (YARU) in New Haven,Connecticut. 
Questions asked of the blood donors included: name, sex, age, occupa¬ 
tion, residences, past serious illness, especially with sore throat and 
difficulty swallowing. In certain cases, including those who claimed to 




Section Two: Serological Tests 
Complement-fixation (CF) tests were done after the method of Casals 
8 
with close adherence to his technique. An extensive and detailed descrip¬ 
tion of this test may be found in Appendix I. YARU lyophilized viral anti¬ 
gens included: chikungunya, strain Ross-passage 170, prepared by Casals; 
Congo, strain K2/61-passage 4; Congo, strain U3010-passage 13, prepared by 
Casals; Mokola, strain IbAn 27377-passage 7; and Bwamba, strain M459-pass- 
age 85. These antigens were prepared by the sucrose-acetone method described 
9 
by Clarke and Casals. In the unlikely possibility that the inactivated 
Lassa antigen (strain LP, <10 passages, obtained from Center for Disease 
Control in Atlanta) might be pathogenic, this CF test was done by Dr. Casals 
who has survived infection with this virus and is presumably immune to it. 
Hemagglutination-inhibition (HI) tests were done by methods described 
10 11 
by Clarke and Casals and by Casals with close adherence to their tech¬ 
niques. A comprehensive description of the method may be found in Appendix 
II. Antigens used were the YARU lyophilized preparations obtained by the 
same sucrose-acetone method that was used in the CF tests and included: 
Bunyamwera, strain original -passage 49, prepared by Casals; chikungunya, 
strain Ross -passage 175; dengue II, strain TH36-passage unknown; Ilesha, 
strain KO/2 - passage 12; Ingwavuma, strain An 4165 - passage 8; West Nile, 
strain B 956 - passage 3; yellow fever, strain Asibi - passage 215; Zika 
strain MR 766 - passage 148. 
The neutralization test (NT) was done after the method of Casals and 
_ 12 
was followed closely. A full explanation of this technique may be found 
in Appendix III. The NT tests were done with the following lyophilized 
viruses: Bunyamwera, strain original - passage 46; Bwamba, strain M 459 - 
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passage 86; chikungunya, Ross strain - passage 176; Ilesha, strain 
KO/2 - passage 12; Ingwavuma, strain An 4165 - passage 8; Zika, strain 
MR 766 - passage 148. The calculation of LD was done after the method 
of Reed and Muench. 
13 

Chapter Two: Survey Data and Test Resu Page 9 
Section One: Survey Information 
Survey data and CF and HI test results from ear Individual who 
donated serum, are given in Appendix IV. A summary of the survey data 
is given in Table 1 and is briefly described below. 
1. Location of serum collection. Of the 165 serum samples: 
56% were obtained in Montserrado County, either at ELWA Hospital or at 
the Maternity Center; 23% were obtained in Bong County at Phebe 
Hospital; 21% were obtained in Loffa County at Curran Hospital in 
Zorzor. To identify locations in the survey, a map of Liberia is given 
on the next page. 
Iz_§ex. Thirty-one percent of samples were from males, and 69% 
were from females. The female predominance is due to an intentional 
effort to collect sera from many hospital personnel. 
3. Occupation. Sixty—three percent of those surveyed were involved 
in health care delivery. The second-most predominant occupation was 
farming, practiced by a known 10% of those surveyed. 
4- Age- The breakdown includes: under 20 years, 8%; 20-29 years, 
39%; 30-39 years, 27%; 40-49 years, 14%; 50 years and older, 8%. None 
of those in the survey were under twelve years. The reason for so few sera 
from those under 20 years, is the added difficulty in obtaining such samples. 
As mentioned earlier, serum collection in villages and outpatient clinics 
was met with poor compliance. Inpatient pediatrics consisted primarily of 
children under five years of age. Because of the technical difficulty in¬ 
volved in obtaining a sufficient quantity of serum with the equipment avail¬ 
able, no attempt was made to collect sera from the pediatric ward. A per¬ 
centage distribution of the population of Liberia by age and sex for 1971 















































































5. Residence. Of all those surveyed: 64% had spent some part of 
their lives in Montserrado County; 36% had lived in Loffa County; 28% 
had lived in Bong County. The other six counties were represented by 
less than 15% of those surveyed. 
6. Serious illness with sore throat and dysphagia. Only eight 
people or 5% of those surveyed, gave this past history. 
In the last four categories answers were obtained from 85-90% 
of those from whom serum was obtained. Thus there remain 10-15% of 




Sunniary of Survey Information 
1 Location of Serum Collection 
ELWA Hospital near Monrovia 
Phebe Hospital near Gbarnga 
Curran Hospital at Zorzor 
Maternity Center in Monrovia 
Number of Sera Percentage 
61 37 X 
37 23 Z 
35 21 % 
32 19 % 
Total 165 100 % 
II Sex 
Male 
Number of People 
51 31 X 
Female 114 69 X 
Total 165 100 % 
III Occupation . . 
. Midwife 
Number of People 
38 23 X 
5 Midwife Student . . • . 24 15 % 
Nurse. . 27 16 X 
Other Health Care Workers 15 9 X 
Total Number of Health Care Workers 104 63 X 
■ '. Farmer . • • • 17 11 % 
Housewife and mother1 .13 8 % 
37 % 
Other 9 6 % 
Unknown .* ■ -20 12 % 
* * - * * \ • • ' " Total -165 100 % 
' IV Age2 . • , / 
'. >Unknown • 
Number of People 
6 35% 
<10 o 0 X 
10-19 13 8 % 
20-29 . . - • . 64 39 % 
• 30-39 , * 45 27 Z 
40-49 23 14 % 
50-59 5 3 % 
160 9 55% ■ 
Total 165 100 % 
3 
V Residence 
Montserrado County - 
Number of People 
106 64 % 
Bong 46 28 Z 
Loffa 60 36 X 
Grand Bassa " 17 10 % 
Cape Mount " 12 7 Z 
Nimba " 18 11 % 
Sinoe 10 6 % 
Grand Gedeh " 4 25% 
Maryland " 7 4 X 
Other 
USA 11 7 X 
Sierra Leone 8 5 % 
Ivory Coast, Guinea, Ghana, Sudan, 
Italy, England, France, India 1 each JbX 
Majority of life outside West Africa, 
total number of non-West Africans 
i. e, 
7 4 X 
VI Serious Illness with Sore Throat, Dysphagia 8 5 X 
Footnotes 
1. The number of housewives and mothers was derived in part from 
patients admitted for obstetrical and gynecological reasons. 
2. In a number of cases the patient did not know his exacc age. 
Thus the ago was estimated as best as possible. 
3. All residences during lifetime of each person are included 
in the numbers given. Thus a person who lived in several 
places is listed as having resided in each one. It must be 
stated that there were about 15-20 people for whom some or 




Percentage Distribution of the 
Liberian Population by Age 




Sexes Male Female 
All Ages 100.0 100.0 100.0 
0-1 yr. 3.1 3.3 2.0 
1-4 yrs. 13.6 14.2 13.2 
5-9 yrs. 14.7 15.2 14.2 
10-14 yrs. 10.2 11.4 9.1 
15-19 yrs. 8.6 8.5 8.8 
20-24 yrs. 7.8 6.2 9.4 
25-29 yrs. 9.1 7.4 10.8 
30-34 yrs. 7.2 6.5 7.9 
35-39 yrs. 6.6 6.6 6.7 
40-44 yrs. 4.9 5.1 4.6 
45-49 yrs. 3.3 4.3 3.3 
50-54 yrs. 3.1 3.4 2.8 
55-59 yrs. 1.9 2.3 1.6 
60-64 yrs. 1.9 2.0 1.7 
65 years 
6 over 3.4 3.8 3.1 
Source: Liberia, 
Economic 
Ministry of Planning and Economic Affairs 
Survey of Liberia 1971. ’ 

Section Two: Complement-Fixation Test Results Page 14 
A summary of the CF tests for the five antigens assayed is given 
in Table 4. The results with each antigen are briefly described below. 
1. Lassa Fever. Of the 165 sera five were positive for Lassa 
Fever. A comprehensive sketch of these five which includes a descrip¬ 
tion of illness, is given in Tables 3-A and 3-B. Three of the people 
were females previously documented as positives by Dr. Thomas Monath 
during a Lassa Fever outbreak in 1972 at Curran Hospital in Zorzor, 
14 
Loffa County. In two of these females the illness was severe, while 
in the third it was relatively mild. A fourth female claimed severe 
illness while at Zorzor in November, 1969. These four women were work¬ 
ing as midwives at the time of illness. All described a clinical pic¬ 
ture compatible with Lassa Fever as known to date, except that the one 
who was ill in 1969 described yellow sclera as part of her illness. 
The fifth positive was a 19 year-old female studying midwifery at Phebe 
Hospital in Bong County. The first 18 years of her life were spent at 
Koindu, Sierra Leone, about 50 miles east of the site of the 1972 Lassa 
15 
Fever epidemic at Panguma, Sierra Leone. She denied ever having been 
seriously ill. 
2. Congo. There was one possible positive by CF. The serum was 
non-specific, but it manifested a stronger fixation of complement in 
the serum wells than in the control wells. Subsequent NT test of this 
serum by Dr. Casals was negative. (Congo virus, strain IbAr 10-200 
passage 13, prepared by Casals). 
3. Mokola. No positive sera were found. 
4. Chikungunya. Although sera were screened at dilutions of 1:4 
and 1:8, end-point titrations were not carried out. Twenty-five sera 
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(15% of all sera) were positive. 
5. Bwamba. End-point titrations were carried out, and the titers 














Momolu Serum Number 14 33 82 92b 178 
Sex Female j Femnle Female Female Female Age 36 19 26 35 28 Occupation Midwife, 5 yr 
1 
Midwife 
Student, 1st yr 
Midwife, 5 yr Midwife, 4 yr Midwife, 8 yr 
Residences by 
county 





n°nS, 1 yr 
Loffa, 7 yr 
Bong, 19 yr 




Duration at Zorzor 3 yrs,1967-70 None 7 yrs Not obtained, 
most likely 
6 yrs 
8 yrs, 1964-72 
-F Titers by 
Monath^ 
Not at Zorzor 
during outbreak 


























Place of Illness Zorzor 1 Zorzor Zorzor Zorzor 
Date of Illness November, 1969 | Not 11l7 Onset 3/21/72 Onqor 3/^0 /l') Length of 
Illness 
Two weeks Few days Four weeks . Not obtained 
Footnotes 
1. Loffa county contains Zorzor, the site of the 1972 Lassa Fever outbreak. 
2« tin t i 1 r\r> O Vo -s r- o r>o Mi oe 1-1__ 11 i ... 
3. 
Until one year ago Miss Foryon had spent all her life at Koindu, Sierra” 
Leone, which is 50 mi. E of Panguma, the site of an outbreak of Lassa 
Fever in 1972. 
Liberian town, county not obtained. 
4. Values of CF titers were obtained from Dr. Monath through correspondence. 
Since no value for the titer of antigen was mentioned, only the serum 
titer is indicated. 
5. Jetta Momolu is most likely the individual named Jetty Ziegler in 
Dr. Monath's study, who was married to Francis Momolu. 
6. CF titers are recorded as: the reciprocal of the serum titer/ the 
reciprocal of^the antigen titer. CF titers are recorded only for sera 
3'*" or fixation of complement. A preliminary screening 
of all sera at a 1:8 dilution of antigen, showed only two positives, 
namely sera it 33 and 92b, both with titers of 4/8. A final screening 
with a 1:4 dilution of antigen was run on about 10 highly suspicious 
6era; and it showed the above five positives. It.is noteworthy that in 
the final screening the endpoints for sera tf 33 and 92b, namely 2/4, 
were below those of the preliminary screening, namely 4/8. 
Although Dr. Monath's communication mentions that Martha Vankpne was 
not ill, tills lady related the above account ol illness. Dates lor the 
onset of illness for Phebe Hallowanger and Jetta Momolu were obtained 
from Dr. Monath. 
7. 

Table 3-B Page 17 
Clinical History of People with Positive CF Test for Lassa Fever1 
Name LS 













Sore throat + 
Difficulty swallowing + + 
Coryza 0 









Respiratory Difficulty + 
Urinary Difficulty 0 

















Low white blood count 







































































fwih31 3re personal accounts, not documented by records. Only In the 
lescent CF te-J ‘r* m°rbld ePlsode documented by acute and conva- 
escent Cr tests which showed >fourfold rise in titer for Lassa. 
+ + = symptom present and very severe. 
+ = symptom present or low white blood count or positive malaria smear. 




CF Test Results Corre lating Antigen with Degree of Seroreactivi tv1 
Negative CF Test 
p 




Lassa 160 Total of 5 sera 
at titer of 2/4 
■ 
3% 
Congo 164 Possibly one serum at 
a titer of 2/83 
<1% 
Mokola 165 0 0% 
Chikungunya 140 
Total of 25 sera 
at the following 
screening titers: 
One serum at 4/8 
Fifteen sera at 8/8 






Total of 11 sera 
at the following 
titers: 
Three, sera at 2/4 
Seven sera at 4/4 




1* Each box indicates the number of serum samples out of a total of 165. 
For Bwamba only 161 sera were assayed because four sera had already 
been used up. 
2. CF tests are recorded as: the reciprocal of the serum titer/ the 
reciprocal of the antigen titer. CF titers are recorded only for 
sera with readings of "3+" or "4+” fixation of complement. Values 
represent end-point titrations for all antigens except chikungunya 
in which only a screening was done with 1:4 and 1:8 serum 
dilutions. 
3. This serum sample was non-specific; but it manifested stronger 
fixation of complement in the serum wells than in the control 
wells. 

Section Three: Hemagglutination-Inhibition Test Results 
Page 19 
A summary of the HI tests for the 8 antigens assayed is given in 
Table 5. Selected aspects of the HI tests with the group B antigens 
are portrayed in Tables 6-A, B, and C. The results with each antigen 
are briefly described below. The serum titers listed below are ad¬ 
justed for inhibition of hemagglutination of 8 units of antigen. Serum 
titers of "<1:10" indicate sera giving hemagglutination-inhibition with 
2-4 units of antigen, which when adjusted to 8 units of antigen, give 
values <1:10. 
1. Chikungunya. 34 sera (21% of total) had a titer of <1:10 or 
higher. Of these 26 sera (16% of total) had titers _> 1:20. 
2. Ilesha. 11 sera (7% of total) were positive, all with a titer 
of <1:10. 
3. Ingwavuma. 6 samples (4% of total) were positive. All had 
titers _< 1:10 except for one serum with a titer of 1:20. 
4. Bunyamwera. 32 samples (19% of total) had a titer of <1:10 
or higher. Of these 6 sera (4% of total) had titers _> 1:20. 
5. Dengue II. 28 sera (17% of total) had a titer of <1:10 or 
higher. Of these 20 sera (12% of total) had titers _> 1:20. 
6. West Nile. 58 samples (35% of total) had a titer of <1:10 
or higher. Of these 26 sera (16% of total) had titers _> 1:20. 
7. Yellow Fever. 51 sera (31% of total) had a titer of <1:10 
or higher. Of these 30 sera (18% of total) had titers _>1:20. 
8. Zika. 42 sera (25% of total) had a titer of <1:10 or higher. 
Of these 23 sera (14% of total) had titers > 1:20. 
9. Group B Antigens. See Tables 6-A, B. C. The four group B 
antigens tested by HI were: dengue II, West Nile, yellow fever, and Zika. 
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For these four all except dengue II reacted with sera which showed 
positivity only to that one group B antigen ( Table 6—A). No sera were 
positive only to West Nile at titers 1:20. Nine sera were positive 
only to Yellow Fever at titers _> 1:20. Four were positive only to Zika 
at titers >_ 1:20. 
Table 6-B indicates the number of sera that were positive to only 
two of the four group B antigens. Table 6-C deals with "broad group B" 
reacting sera, i.e., those serum samples which were positive to all four 
group B antigens. Eighteen sera (11% of total) showed HI positivity to 
all four group B antigens at a titer of <1:10 or higher. Of these 13 
sera (8% of total) showed positivity to all four antigens at titers >1:20. 
Finally of the 165 serum samples, 94 had HI antibodies (titer of 
<1:10 or higher) to one or more of the four group B members. Thus 57% 
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Tables 6 -A,B,C 
Selected HI Test Results with Group B Antigens 
Table 6 -B 
Number of Sera Reactive to Only Two of the Four Group B Antigens^ 
Number of Sera 
Reactive to Dengue II and West Nile 2 
Reactive to Yellow Fever and Zika 1 
Reactive to West Nile and Yellow Fever 4 
Reactive to West Nile and Zika 6 
. .. _ _ I 
Footnote 
1. Each box indicates the number of serum samples out of a total of 
165, inhibiting hemagglutination of 8 units of the indicated 
group B antigens. Serum titers for these reactions range from 
"<1:10" upward. See Table 5 for a listing and explanation of 
these serum dilutions. While other combinations are possible, 
no other combinations for reactions to only two of the four 
group B antigens were observed. The four group B antigens are: 
dengue II, West Nile, yellow fever, and Zika. 
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Tables 6 -A,B,C 
Selected HI Test Results with Group B Antigens 
Table 6 -C 
Number of Sera Reactive to All Four Group B Antigens^ Percent 
Total number of sera in which serum titer 
was >0 for all 4 Group B antigens 18 11% 
Total number of sera in which serum titer 
was >. 1:20 for all 4 Group B antigens 13 8% 
Footnote 
1. Each box indicates the number of serum samples out of a 
total of 165, inhibiting 8 units of each of the four 
group B antigens. Serum titers for reactions in the upper 
box range from "<L:10" upward. Serum titers for reactions 
in the lower box (which is a subset of the upper box) 
range from 1:20 upward. See Table 5 footnote for listing 




Section Four: Neutralization Test Results 
Neutralization tests were done with six viruses in order to confirm 
the results of the CF and HI tests. The six NT's are displayed in Tables 
7- A through 7-F. All six tests had adequate and valid controls. Tables 
8- A through 8-F correlate the results of each NT test with the correspond¬ 
ing CF and/or HI tests. These correlations are described below. A non- 
protective serum is here defined as one in which there are 0-2 survivors 
from the original litter of 8 mice. A protective serum is defined as one 
in which there are only 0-2 deaths attributable to the virus from the ori¬ 
ginal litter of eight mice. A partially protective serum is defined as 
one which does not fall into the other two categories. 
1. Zika. (Tables 7-A and 8-A). The 3 sera positive by the HI test 
to Zika virus but not to other group B antigens neutralized Zika virus in 
mice; of 6 sera positive for Zika and for 1 or 2 group B antigens, 3 pro¬ 
tected against Zika in the neutralization test and 3 did not. Eight sera 
positive to all 4 group B antigens failed to protect mice against Zika. 
Three sera negative to all 4 group B antigens and 3 positive to an antigen 
other than Zika, also failed to protect mice against Zika. 
2. Bwamba. (Tables 7-B and 8-B). Of the six CF negative sera, two 
gave protection and four gave no protection from the virus. Of the eleven 
CF positive sera, eight were protective and three were not. 
3. Ilesha. (Tables 7-C and 8-C). Of the six HI negative sera, five 
were protective and one was not. Of the eleven HI positive sera: nine 
neutralized the virus; one partially neutralized the virus; and one failed 
to neutralize the virus. 
4. Ingwavuma. (Tables 7-D and 8-D). All five HI negative sera and 
all six HI positive sera failed to protect against the virus. 
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5. Chikungunya. (Tables 7-E and 8-E). All six sera shown to be 
negative by both CF and HI tests, failed to protect against the virus. 
All eleven sera shown to be positive by both CF and HI tests, protected 
against the virus. 
6. Bunyamwera. (Tables 7-F and 8-F). Of the six HI negative sera: 
one was protective; one was partially protective; and four were non-pro- 
tective. Of the thirteen HI positive sera: two were protective; two 
were partially protective; and nine were nonprotective. 

Table 7-A 






















































































































































Liberian Human 9 7 
" 9 8 
" "99 
" " 9 11 
" " « 12 
" " # 14 
" " 9 15 
" " 9 20 
" " 9 22 
" " 9 23 
" " 9 24 
" " 9 27 
" " 9 31 
" 0 38 
" 9 81 
" " 9 94 
" 9 103 
” ” # 111 
" 9 121 
" " 9 123 
" " 9 131 
" " 9 139 

















































































































Number of LD 
50 
for NT « eight.10 
Footnotes 
1. Test was run from 5/20/75 to 6/3/75. Zika virus used in NT consisted 
of a wet pool, made from 10% baby mouse brain suspended in 7.5% bpa 
Virus for the wet pool came from YARU lvophilized Zika, passage tl 148 
harvested 2/21/68 and freeze-dried 3/25/68. 
2. Each litter consisted of 3- or 4-day-old mice, eight in number. 
Inoculated intracerebrally with app. 0.02cc. 
3. Dilutions of virus were made with 0.75% bpa 
4' addln^T" \r vi—citic-fluid mixtures'for inoculation were made by 
adding virus to an equal volume of serum or ascitic fluid,respectively. 
k, b^ore the viral disease began or under circumstances 
not possibly attributable to the virus, are not included in the 
determination of deaths or survivors. 
6* l*10einMMr/eCflrder 33 nUmber °f tw°-fold dilutions beginning at 
*«mu"* 8 tS 0t ar>tigen. Values recorded as 0-1 indicate sera 
"8 lnhlb*tlon to one or two dilutions with 2-4 units of antigen 
areCotb Y JU C° 8 U"itS °f ^ values <1:10. Values 
are otherwise not recorded when titer <1:10. 
7‘ 8/27/66-9/28/66?ted °f ^ lmnmne a3cicic fluid* VARU lyophilized 
8‘ 7/10/70-7/2^70. °f n0rn’al m°USe aSCitic fluld’ YARU lvophilized, R 16208, 
9. Dilutions for titration were made by adding virus to an equal volume 
of the same NMAF described in foocnote 8 
10‘ SeSrar?oUo? f* “"tainl>' ln *”or for the following reason. 
The ratio of deaths/survivors for litter 0 07149 should have 
corresponded more closely to those for litters 9 07147 and 07148, 
because they all were supposed to contain the same virus dilution 
of 10 .along with the same NMAF All dilutions for the titration 
were derived from a different IQ'S poo, tll.in tho , ' 
inoculate all the other Utters. The values for l.D< 
number of LI) 
J pool used to 
u50 mu! for the 
j'> , _ .‘fore differ from those 
corresponding to the litters outside of titration. The NT still 
has some validity, however, because the NMAF controls and the 
7.ikn MI At* controln are >‘.u0ci. 
’^50 ^or NT, must the 

Table 7-B 


































































07157 Iq-3.8 Liberian Human If 22 8/0 
58 M II If If 24 2/6 
59 II 
II II 
tf 27 0/8 4/4 
07160 II II II t 46 8/0 
61 II II II H 49 8/0 
62 II II II # 51 1/7 
63 II II II t 65 1/7 4/4 
64 II • 1 II # 67 8/0 4/4 
65 M II II # 75 8/0 4/4 
66 II II II t 93 0/8 8/4 
67 II II 91 S 104 5/2 
68 II II II 0 129 1/7 4/4 
69 II II II t 136 0/8 2/4 
07170 II • 1 II # 153 0/8 2/4 
71 It II It 8 170 0/8 2/4 
72 It II It t 171 8/0 4/4 
73 • 1 II II If 180 0/8 4/4 
07174 II Bwamba MIAF7 1/7 
75 II II II 2/5iU 




78 IQ-4'8 " LD50= 7/0 
79 IQ'5'8 Number of LD,q 2/4 
-5.8 
07180 10 " for NT = 80. 4/3 
81 io‘6-8 II 0/8 
82 10-7-8 II 0/8 
Footnotes 
1. Test was run from 5/20/75 to 6/3/75. Bwamba virus used in NT 
consisted of a wet pool, made from 10% baby mouse brain suspended 
In 7.5% bpa. Virus for the wet pool came from a preliminary wet pool 
which came from YARU lyophilized Bwamba, passage If 86, 12/8/61. 
2. Each litter consisted of 4- or 5-day-old mice, eight in number, 
inoculated intracerebrally with app. 0.02 ml. 
3. See footnote 3, Table 7 -A. 
4. See footnote 4, Table 7-A. 
5. See footnote 5, Table 7-A. 
6. CF tests are recorded as: the reciprocal of the serum titer/ the 
reciprocal of the antigen titer. CF titers are recorded only for sera 
with readings of "3+" or "4+" fixation of complement. The titers 
recorded represent end-points . 
7. Bwamba MIAF consisted of lyophilized NIH Polyvalent Bwamba mouse immune 
ascitic fluid, catalogue no. G 212-601-567. 
8. NMAF consisted of normal mouse ascitic fluid, YARU wet frozen 5/16/74. 
9. Dilutions for titration were made by adding virus to an equal volume 
of the same NMAF described in footnote 8. 
10. Small size of the mice in this litter, suggests poor care by mother 
as cause of deaths. 

Table 7-C 








































































07183 lO-4,3 Liberian Human If 24 0/8 
84 
ff " " If 56 0/8 1 
85 
It " " If 67 0/8 1 
86 " ! " " If 69 1/7 
87 
if 
" " S 71 0/8 
88 
ft " " If 73 1/6 
89 
ft " " 0 88 1/7 1 
07190 
tt 
" " # 92b 0/8 1 
91 
tt •i .i ^ 93 8/011 1 
92 
tt 
" " S 95 0/8 1 
93 
tt 
" " If 119 0/8 1 
94 
tt " " S 126 0/8 1 
95 
tt 
" " if 139 8/0 
96 
tt 
" " # 143 0/8 1 
‘ 97 
tt 
" # 145 0/8 1 
98 
tt 
" " 0 153 1/7 
99 
tt 
" " If 171 4/4 1 
07200 
tt Ilesha MIAF7 0/8 
01 






07203 10~4,3 Titration^ 8/0 
04 10-5-3 " LD50= 10”6'2 7/0 
05 lO"6'3 Number of LD^q 3/4 
06 lO'6*3 " for NT = 80. 4/4 
-7.3 





1. Test was run from 5/21/75 to 6/3/75. Ilesha virus used in NT 
consisted of a wet pool, made from ]0% baby mouse brain suspended 
in 7.5% bpa. Virus for the wet pool came from YARU lyophilized 
Ilesha, passage If 12, R5964, 3/21/68. 
2. Each litter consisted of 4-day-old mice, eight in number, inoculated 
intracerebrally with 0.02ml. 
3. See footnote 3, Table 7-A. 
4. See footnote 4, Table 7-A. 
5. See footnote 5, Table 7-A. 
6. See footnote 6, Table 7-A. 
7. Ilesha MIAF consisted of YARU lyophilized Ilesha mouse immune 
ascitic fluid, WHO ATCC, R 3483, inact. 12/6/67. 
8. See footnote 8, Table 7-B. 
9. See footnote 9, Table 7-B. 
10. Mother of litter died on 6th day of test. 
11. Average survival time of this litter was 9.3 day, double that for all 









































































07209 10"4-3 Liberian Human it 24 8/0 2 
07210 
ft II 
" it 26 8/0 
11 II " it 32 8/0 0-1 
12 It " # 38 8/0 
13 It " # 67 8/0 0-1 
14 II " * 77 8/0 
15 II " $ 78 8/0 
16 It " it 80 7/0 
17 II " t 96 8/0 
18 II " # 115 6/2 0-1 
19 II " it 119 7/1 0-1 
07220 II " # 139 8/0 1 
07221 
• 1 7 
Ingwavuma MIAF 0/7 




07224 10~4*3 Titration^ 8/0 




25 lo"6-3 it Number of LD^q 6/2 
27 IQ"6*3 it for NT = 320 7/1 
28 10-7'3 ii 0/8 
-8.3 





1> Test was run from 5/26/75 to 6/6/75. Ingwavuma virus used In NT 
consisted of a wet pool, made from 10% baby mouse brain suspended 
In 7.5% bpa. Virus for the wet pool came from YARU lyophilized 
Ingwavuma, passage it 8, harvested 4/18/68 and freeze-dried 4/23/68. 
2. Each litter consisted of 4-day-eld mice, eight in number, inoculated 
intracerebrally with app. 0.02ml. 
3. See footnote 3, Table 7-A. 
4. See footnote 4, Table 7-A. 
5. See footnote 5, Table 7-A. 
6. See footnote 6, Table 7-A. 
7. Ingwavuma MIAF consisted of YARU lyophilized Ingwavuma mouse immune 
ascitic fluid, MG 42756, 3/21/66. 
8. See footnote 8, Table 7-B. 






Neutralization Test: Chikungunya1 
0> QJ 
■U -O 
































































10 * Liberian Human tf 7 8/0 
31 !t " tf 22 0/8 8/12 5 
32 II " tf 24 1/7 4/8 4 
33 • I " tf 26 0/8 8/12 4 
34 " tf 28 0/8 8/12 2 
35 II " tf 31 8/0 
36 II " tf 38 0/8 8/12 5 
37 II " # 52 8/0 
38 II " tf 55 8/0 
39 II " tf 66 8/0 
07240 tf II " tf 87 0/8 8/8 4 
41 II " tf 96 0/8 8/8 5 
42 II " tf 97 8/0 
43 II " tf 104 0/8 8/8 6 
44 " # 123 0/8 8/8 1 
45 " tf 126 0/8 8/8 1 
46 " tf 135 0/0 8/8 2 
07247 • 1 Chikungunya MIAF® 0/8 
48 II II 1/7 
07249 II NMAF9 7/0 
07250 
-4.9 







52 10 II Number of LD^q 3/5 
53 io-6-9 II for NT = 50. 2/6 
-7.9 
54 10 II 0/5 
55 io"8-9 II 0/8 
Footnotes 
1* ^est was run from 5/27/75 to 6/0/75. Chikungunya virus used in NT 
consisted of a wet pool, made from 10% baby mouse brain suspended- 
in 7.5% bpa. Virus for the wet pool came from YARU lyophilized 
Chikungunya, passage tf 176, harvested 2/6/70 and freeze-dried 2/23/70. 
Each litter consisted of 2-day-old mice, eight in number, inoculated 
intracerebrally with app. 0.02ml. 
See footnote 3, Table 7 -A. 
See footnote 4, Table 7 -A. 
See footnote 5, Table 7 -A. 
CF tests are recorded as: the reciprocal of the serum titer / 
the reciprocal of the antigen titer. CF titers are recorded only 
for sera with readings of "3+" or ”4+” fixation of complement. Titers 
recorded do not represent end-points but reflect only a screening 
with 1:4 and 1:8 dilutions of serum. 
7. See footnote 6, Table 7 -A. 
8. Chikungunya MIAF consisted of lyophilized Chikungunya TH 35 mouse 
immune ascitic fluid, MG 43026, 4/20/66. 
9. See footnote 8 on Table 7 -11. 









































































10~6.5 Liberian Human It 21 8/0 
57 ft " " 0 22 6/2 1 
58 If fi ” # 23 8/0 2 
59 It " " 0 24 8/0 3 
07260 II ” .. § 31 8/0 1 
61 
ft " " Q 32 8/0 1 
62 fl " " it 35 8/0 
63 
If " " 9 38 8/0 2 
64 fl " " It 39 6/2 
65 
f* ” " It 42 8/0 2 
66 
It " " 9 93 4/4 
67 fl " " 9 95 8/0 
68 
M 
" " 9 97 5/3 1 
69 
If 
" " # 122 8/0 0-1 
07270 fl " " It 126 0/8 
71 If " " It 139 8/0 2 
72 If " " 9 145 4/4 0-1 
73 
ft 
" " # 153 0/8 4 
74 ft " " It 164 0/8 0-1 
07275 fl Bunyamwera MIAF7 0/8 
76 If II If 0/8 
07277 




79 Kf7-5 " LD50=10“8'7 8/0 
C7280 io-8-5 Number of LD^ 4/4 
-8. ^ 
81 10 " for NT = 160 6/2 
-9.5 
82 10 0/8 
-10.5 
83 10 If 0/8 
Footnotes 
1. Test was run from 5/28/75 to 6/9/75. Bunyamwera virus used in NT 
consisted of a wet pool, made from 10% baby mouse brain suspended 
in 7.5% bpa. Virus for the wet pool came from a preliminary wet 
pool which came from YARU lyophilized Bunyamwera, passage It 46, 
R 5882, freeze-dried 3/14/68. 
2. Each litter consisted of 5-day-old mice, eight in number, inoculated 
intracerebrally with app. 0.02ml. 
3. See footnote 3, Table 7-A. 
4. See footnote 4, Table 7-A. 
5. See footnote 5, Table 7-A. 
6. See footnote 6, Table 7-A. 
7. Bunyamwera MIAF consisted of YARU lyophilized Bunyamwera mouse 
immune ascitic fluid, 12/12/67. 
8. NMAF consisted of YARU wet-frozen normal mouse ascitic fluid. 
Sarcoma 180, 5/1/69. 
9. Dilutions for titration were made by adding virus to an equal 
volume of the same NMAF described in footnote 8. 

Tables 8-A through F 
Correlation of CF and HI Test Results with NT Test Results 
On Selected Sera from the 165 Serum Samples 
Table 8-A 
Page 33 
Correlation of Group B HI Test Results with Zika NT Test Results' 
HI Negative to All Four 
Group B Antigens 
HI Negative to Zika 
Antigen, but HI Positive 
to One Other Group B 
Antigen 




HI Positive to Zika 
Antigen plus One or Two 
Other Group B Antigens 
HI Positive to All Four 
Group B Antigens 
HI Positive to Zika 
Antigen, but HI 
Negative Vo All Other 
Group B Antigens 
Footnote 
1. This table is derived from Table 7-A. Numbers in boxes indicate 
how many sera with the designated HI seroreaction responded in the 
indicated manner to challenge with the virus. A non-protective 
serum is here defined as one in which there are 0 to 2 survivors 
from the original litter of eight mice. A protective serum is 
defined as one in which there are only 0 to 2 deaths attributable 
to the virus from the original litter of eight mice. A partially 
protective serum is defined as one which does not fall into the 
other two categories. 
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Tables 8 -A through F 
Correlation of CF and HI Test Results with NT Test Results 
On Selected Sera from the 165 Survey Samples 
Table 8 -B 
Correlation of Bwamba CF Test Results with Bwamba NT Test Results^- 




CF Negative to Bwamba 4 0 2 6 
CF Positive to Bwamba 
with End-point Titer of: 
2/42 0 0 3 3 
4/4 3 0 4 7 
8/4 0 0 1 1 
Footnotes 
• This table is derived from Table 7— B. Numbers in boxes indicate 
how many sera with the designated CF seroreaction responded in the 
indicated manner to challenge with the virus. See Table 8-A, 
footnote 1 for definitions of"non-protective”, "protective", and 
"partially protective". 




Tables 8 -A through F 
Correlation of CF and HI Test Results with NT Test Results 
On Selected Sera from the 165 Survey Samples 
Table 8 -C 
Correlation of Ilesha HI Test Results with Ilesha NT Test Results1 
y-- - -  nuoui L o 
Neutralization Test with Ilesha Virus ---r 
Non-protective Partially 
Protective 
Protective Total | 
HI Negative to Ilesha 1 ' 0 5 6 
| 
HI Positive to Ilesha 1 1 9 11 
L_1 
Footnote 
1. This table is derived from Table 7 -C. See Table 8 -a, footnote 1, 
for definitions of "non-protective", "protective" and "partially 
protective". 
Table 8 -D 
Correlation of Ingwavuma HI Test Results with Ingwavuma NT Test Results1 
--- "... x ICbL. AeblllLb 
Neutralization Test with Ingwavuma Virus 1- 
Non-protective Partially 
Protective 
Protective Total J 
HI Negative to Ingwavuma 5 0 0 
i 
5 




1. This table is derived from Table 7-D. See Table 8-A, footnote 1 




Tables 8 -A through F 
Correlation of CF and HI Test Results with NT Test Results 
On Selected Sera from the 165 Survey Samples 
Table 8 -E 
Correlation of.Chikungunya CF and HI Results with Chikungunya NT Results1 —-  -— wuKvun^uayd 1 X\eSU±LS 




^F+HI Negative to Chikungunya 6 0 0 6 
U.F+HI Positive to Chikungunya 0 0 11 11 
Footnote 
1. This cable is derived from Table -7-E. Numbers in boxes indicate 
how many sera with the designated CF and HI seroreactions 
responded in the indicated manner to challenge with virus. See 
Table 8 -A, footnote 1 for definitions of "non-protective1' 
protective", and "partially protective". 
Table 8 -F 
Correlation of Bunyamwera HI Test Results with Bunvamwera NT Test Results1 
Footnote 
1. This table is derived from Table 7-F. See Table 
for definitions of "non-protective", "protective" 
protective". * 
8 -A, footnote 1, 
and "partially 

Chapter Three: Discussion 
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Section One: Survey Population 
The survey population, as described in chapter two, section one, 
has certain characteristics which set it apart. First there is a 
female predominance of 69%. As previously mentioned, this was due to 
an intentional effort to obtain sera from hospital personnel. Indeed 
63%, almost two-thirds of those surveyed were involved in health care 
delivery. In one respect the weighted selection of hospital personnel 
is advantageous, namely for answering questions about nosocomial out¬ 
breaks of viral infections, such as have been documented for Lassa 
17 16 T 
Fever. In another respect it is not advantageous, since it may not 
give an accurate representation of the viral exposures of both men and 
women who work outside of hospitals and who constitute the vast majority 
of the population of Liberia. The hospital sampling method is also skewed 
in representing less exposure to arboviruses than the general population 
because the work is inside, thus making the workers less accessible to 
insect vectors. At the same time the hospital sampling method is also 
skewed in representing more exposure to respiratory infections because 
of exposure to patients. 
Age is another aspect of skewing of the survey. Eighty percent of 
those surveyed are within the range of 20 to 49 years of age. Only 8% of 
the people were under 20 years, and similarly, only 8% of the people were 
50 years or older. As previously mentioned, the median age in Liberia is 
under 20 years. Therefore the survey is highly biased against this age 
group, and it is highly biased towards those who are over 20 years of age. 
It is entirely possible that viral exposure may have been different at the 
lower end of the age spectrum. One cannot also identify the age at which 
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infection occurs. Nor can one identify whether differencies, if any, 
in age groups is due to longer exposure or to more intense exposure 
at one age. Finally in areas where there is a tendency to multiple 
infections by related viruses, one is more apt to find serological 
patterns of initial infections of that virus group in children, as 
opposed to adults.'^ 
A final skewing of population concerns the fact that only three 
of the nine counties of Liberia, are substantially represented as 
areas of past or present residence. These counties are Montserrado, 
Bong, and Loffa. Therefore one should keep in mind that viral exposure 
may be different in the areas underrepresented by the survey. 
In conclusion, because of the biased method of selection, the survey 
population is not a good random sample of the population of Liberia. Be¬ 
cause of this and because even the most ideal survey may exclude people 
with positive findings, one must refrain from deciding definitively against 
the occurrence in Liberia of human exposure to any of the viruses for which 
no seropositivity was found. For the same reasons one must also refrain 
from using the survey to draw any final conclusions about the incidence in 
Liberia of human exposure to any viruses for which seropositivity has been 
demonstrated. The survey does not reflect the number at risk in the general 
population. For diseases of low incidence and those requiring special types 
of exposure, such as arboviruses, the only valid result is a positive one in 
the type of sample obtained; and even if positive, these results cannot in¬ 
dicate its extent or age/sex distribution. 

Section Two: Serological Test Results 
Prior to discussion of the test results with the Liberian sera, 
a few comments would be in order concerning the lifespan and specifi¬ 
city of CF, HI, and NT antibodies. Concerning the lifespan of these 
three types of antibodies, CF antibodies generally remain at high 
18 
levels for the shortest length of time following infection. With re¬ 
spect to arboviruses it has been stated that CF antibodies remain only 
transiently at a high titer, often vanishing or dropping quickly to 
barely detectable levels within several months to a year after acute 
19 
infection. However, there is definite evidence that CF antibodies 
to arbovirus infections may also last longer. In a five year follow¬ 
up on human cases during an epidemic of St. Louis encephalitis in¬ 
fection, Bond found CF antibodies to be still detectable at levels of 
20 
>1:8 in seven out of nine cases. There is also evidence that for 
21 
dengue virus they exist for as long as 20 years. HI antibodies are 
generally of longer duration than CF antibodies. However they do not 
22 
remain at high levels for as long a time as do NT antibodies. There¬ 
fore if one uses CF and/or HI assays to screen sera, which indeed was 
the case with the Liberian sera, one must realize that a negative re¬ 
sult will be obtained with those sera which no longer have detectable 
levels of CF and HI antibodies due to the passage of time but which 
nonetheless still have NT antibodies. 
Besides lifespan one must consider the specificity of CF, HI, and 
NT antibodies. In general CF and HI antibodies are less specific than 
NT antibodies. Cross-reactions between related viruses are usually 
more pronounced by CF or HI tests and less pronounced by NT. However, 
"it has become increasingly apparent that overlaps by neutralization 
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test occur,.... The capacity of a serum to neutralize a virus is not 
necessarily proof of previous exposure of an individual virus, parti¬ 
cularly in cases where successive exposure to several members of an 
u 23 
antigenic group may result in wide cross-reactivity. One must keep 
in mind that the definition of a group of arboviruses involves sero¬ 
logical cross-reactivity of the member viruses with one another, us- 
24 
ually by CF and HI tests, but also by NT. Because of this overlap, 
serological diagnosis often requires the use of two or all three types 
of serological tests and the use of several or all closely-related 
25 
group members known to exist in the geographic region of the survey. 
However one may still not be able to arrive at a diagnosis. In this 
case the most that can be said, is that the person was infected with 
one or more members of that group of arboviruses. One must also keep 
in mind that positive serological results may be due to infection by 
an undiscovered virus which overlaps immunologically with agents used 
in the assay. 
One must also consider the sensitivity of the CF, HI, and NT tests. 
It must be acknowledged, however, that no absolute standard is available 
to measure the sensitivity of these various tests for arbovirus infec- 
26 
tion. The question of the relative sensitivity of these three tests 
must be posed for each individual virus separately, because one cannot 
assume that results for any given virus can be extrapolated accurately 
to another virus. Unfortunately, the question of relative sensitivity 
of these assays remains largely unanswered for many viruses, including 
many of the viruses in this survey. For one of the best - studied arbo¬ 
viruses, yellow fever, this question has been answered to some degree. 
For yellow fever the HI test has been shown to be more sensitive than 
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the CF test. In humans Infected with this virus as a primary infection, 
HI antibodies usually appear before CF antibodies, reach higher geometric 
O -j 
mean titers, and persist longer than CF antibodies. 
It is really not possible in a quantitative manner to compare the 
sensitivity of CF and HI tests with the mouse neutralization tests, which 
were used in this Liberian survey. Only undiluted serum is used in the 
mouse NT test, whereas the serum is diluted out to end-point in the CF 
and HI tests. However because serum is diluted in tissue culture NT 
tests, it is possible to compare the sensitivity of these tests with 
those of the CF and HI tests. In general it may be stated that CF titers 
have a maximum of less than 1:1000 while simultaneous HI titers may be 
28 
over 1:10,000. NT titers may also be over 1:10,000 for 50% plaque 
reduction. 
Another important consideration in screening sera, is the initial 
serum dilution that is used. The lower the serum dilution, the more likely 
will be the possibility that a positive test result will reflect the pre¬ 
sence nonspecific complement-fixation or nonspecific hemagglutination- 
inhibition. Thus there is a disadvantage to having the initial dilution 
too low. If one uses a higher dilution as the initial titer, one will 
eliminate more of the falsely positive sera. However at the same time one 
will also screen out some weakly positive sera that reflect genuine viral 
infection. Thus one wants to choose an initial serum dilution that is 
neither to high nor too low. Nevertheless one must always be cognizant 
that a positive serological result may be due to nonspecific complement- 
fixation, nonspecific hemagglutination-inhibition or nonspecific neutrali¬ 
zation. To be sure, attempts are made to remove the substances responsible 
for these reactions or to identify their presence by running controls. 
However these attempts are not always successful. 

1. Lassa Fever. 
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Lassa virus is a member of the Tacaribe virus group which belongs 
to the genus Arenavirus. It is the only member of the Tacaribe group 
29 
known to exist in Africa. The virus has been isolated from humans in 
Nigeria, Sierra Leone, and Zorzor, Liberia. NT antibodies have also 
30 
been identified in human sera from Guinea. Consistent with the Tac¬ 
aribe group, is the finding of the Lassa virus in rodents in Sierra 
31 
Leone. There is no evidence to support transmission by arthropod 
_ 32 
vectors. 
As previously mentioned, five CF positives for Lassa were found 
from the 165 sera in the survey (Chapter Two, Table 3). A preliminary 
CF screening of all sera was done using either a 1:4 of 1:8 dilution of 
antigen with 1:4 and 1:8 dilutions of serum. This initial screening 
revealed only two positives; among the negatives were sera from two 
persons who stated that they had Lassa Fever, confirmed by laboratory 
33 
test. These were two of the CF positives from Monath's study in Zorzor. 
A final retest by CF was done with serum samples from the following 
people: the two CF positives in the initial screening, the two CF nega¬ 
tive in the initial screening who were positive in Monath's study, and 
all those in the survey who gave a history of serious illness with sore 
throat and dysphagia. In this final screening the antigen dilution was 
1:4 and the serum dilutions were two-fold, beginning with undiluted serum, 
as opposed to beginning with 1:4 diluted serum in the initial screening. 
From this an additional three CF positives were uncovered, bringing the 
total to five. These three additional CF positive included the two who 
were CF negative in the initial screening who were positive in Monath's 
study; the third was a woman who gave a history of sore throat, dysphagia, 
and serious illness while working as a midwife at Zorzor in 1969. Thus 
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on the basis of retest, Casals states that these five sera are all clear- 
cut positives. Thus all 3 people in the survey who claimed to have Lassa 
Fever were CF positive; there were no people in the survey who claimed to 
have Lassa Fever but were CF negative. Approximately 10 samples were 
tested at this lower serum dilution of 1:2. One cannot help but speculate 
whether any additional CF positive sera might be uncovered by doing a 
final screening on the remaining 155 samples with serum dilutions below 
1:4. However the relative paucity of antigen makes this study implausible 
for the present. One might also speculate whether additional positive sera 
might have been uncovered by using mouse brain Lassa antigen, instead of the 
Vero cell antigen, which is less sensitive. However, the Vero antigen is 
the only preparation now available. H 
One observation to be made from this assay, concerns the apparent 
rate of decline of Lassa CF antibodies (Chapter Two, Table 3). The three 
women documanted by Monath as having Lassa Fever, were CF positive at 
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serum dilutions of 1:32 or 1:64 between April and June of 1972. Between 
October and December of 1974, when the sera for this survey were obtained, 
the titers recorded as 1:2 of 1:4. However, comparison of the CF titers by 
Monath with these recent titers cannot be entirely regarded as valid. Be¬ 
sides the possibility of variation in technique, there is the fact that the 
antigens were different. Monath used a mouse brain antigen, while the 
antigen used more recently by Casals is a Vero cell antigen. Casals has 
had occasion to run both antigens simultaneously on some sera, and he has 
found the mouse brain antigen to be more sensitive. D Since the sera col¬ 
lected by Monath in 1972 are still available at the Center for Disease Con¬ 
trol in Atlanta, it would be worthwhile to do simultaneous CF tests on the 
paired sera, in order to minimize any variation in technique and any vari¬ 
ation in antigen. One must bear in mind the possibility that some of those 
in the survey may have had Lassa Fever but are no longer identifiable, be¬ 
cause of the disappearance of CF antibodies. 
\ 
Another finding from the survey, is the absence of evidence for 
the occurrence of Lassa CF antibodies outside the areas for which the 
existence of the virus has already been documented. Besides the three 
women who were documented at Zorzor by Monath, a fourth CF positive in 
the survey was a woman who in 1969 at Zorzor, contracted a severe illness 
entirely compatible with all other cases of Lassa Fever, except for 
sclericterus. Since this woman spent her entire life in Loffa County 
except for the four years prior to survey, during which she lived outside 
Monrovia, it seems most likely that she contracted her infection in the 
area of Zorzor. Similarly the fifth CF positive in the survey was obtained 
from a woman who spent her entire life in Koindu, Sierra Leone except for 
the year prior to survey, during which she lived near Phebe Hospital in 
Bong County. This fact suggests that she contracted her infection while 
she lived in Koindu, which is 50 miles from the documented outbreak of 
37 
Lassa Fever in Panguma, Sierra Leone. To be sure these last two persons 
may have contracted their illness in other areas or from people who con¬ 
tracted their illness in other areas. However the majority of their lives 
were spent in areas already known to contain Lassa virus. One must keep 
in mind that even if all of the positives in this survey did occur in 
areas already known to contain Lassa virus, it is still entirely possible 
that the virus may exist in other areas of Liberia. To make any other 
conclusion would be unwarranted, because of: 1) the shewing of this survey 
population; 2) the limited number of specimens; 3) and the short lifespan 
of CF antibodies; and 4) the sensitivity of the test and the dilution used. 
A significant observation from the survey is the wide spectrum of the 
degree of illness with Lassa Fever (Chapter Two, Table 3). Of the three 
cases documented by Monath, two were severly ill, and the third was only 
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mildly ill, still being able to work. The fourth person who was also 
at Zorzor was seriously ill. The seropositive person from Sierra Leone 
denies ever being seriously ill. This is consistent with observations 
which show that subclinical infection or mild forms of the disease may 
38 
occur. Even if the illness is severe, the clinical onset is often 
39 
very non-specific. For these reasons the disease may elude recognition 
by health care workers and thereby lead to further propagation of the 
virus to other people. While discussing the clinical recognition of 
the disease, it is worth remarking that all four people from Zorzor 
described sore throat and difficulty swallowing as part of their illness. 
This is consistent with the findings of the three major epidemics descri¬ 
bed in the literature. In the 1970 epidemic in Jos, Nigeria 19 or 23 
cases (83%) had pharyngitis.^ in the 1972 epidemic in Panguma, Sierra 
41 
Leone 9 of 11 cases (82%) had pharyngitis. In the 1972 epidemic in 
42 
Zorzor, Liberia all 10 cases (100%) had pharyngitis. Most of these 
cases had severe sore throat; in turn most of the cases with sore throat 
also had dysphagia. In the Sierra Leone epidemic this pharyngitis was 
characterized by reddening of tonsillar and peritonsillar tissues, soft 
palate and posterior pharynx, with raised patches of yellowish exudate 
occasionally coalescing into a pseudo-membrane. Ulcerations resembling 
typical aphthous ulcers were seen in only one of the 11 patients in Sierra 
43 
Leone. To be sure sore throat, dysphagia and pharyngitis are not specific 
for Lassa Fever. Indeed these may be due to bacterial agents such as 
Streptococcus or other viral agents. However there is no data available 
by laboratory documentation on the incidence of any of these infective 
agents in Liberia. Nevertheless, it has been recommended that in a known 
or suspected area in West Africa, the diagnosis of Lassa Fever should be 
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considered "for any person with fever, generalized malaise, and myalgia, 
especially if sore throat or pharyngitis are present. Any adult patient 
who enters a hospital in West Africa with these symptoms and who is 
found to be leukopenic, should ideally be hospitalized at once in an 
44 
isolation ward". The presence of leukopenia would differentiate it 
from the usual streptococcal infection in which leukocytosis is charac¬ 
teristic. 
One final comment about Lassa virus concerns its relationship to 
hospital contagion. Some of the documented outbreaks involved an index 
case being brought into the hospital, and here the disease was trans- 
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mitted to other patients and to hospital personnel. Because hospital 
work may afford increased opportunity to contract the virus from patients 
or from other hospital personnel, a deliberate attempt was made in this 
survey to collect as many sera as possible from those employed in health 
care delivery. Of the 104 health workers in the survey, five had CF 
antibodies to Lassa. The three positives documented by Monath were all 
midwives. The fourth claimed to be sick while working as a midwife at 
Curran Hospital in Zorzor. There is a good possibility, however, that 
the fifth CF positive person contracted her illness before she began 
health care work, i.e., while she lived at Koindu, Sierra Leone. Of the 
61 samples obtained from those who were not connected with health care, 




Congo virus is a member of the Crimean Hemorrhagic Fever-Congo group, 
46 
of which Congo is the only member known to exist in Africa. The virus 
has been isolated from humans in the Congo and Uganda. It has also been 
isolated from Nigerian cattle and from ticks in Nigeria and Senegal.^ 
Thus the virus is enzootic in West Africa, although the virus or anti¬ 
bodies to the virus have not been found in humans from this region. The 
results of the Liberian survey add no new findings. All sera were nega¬ 
tive by CF test except for a questionable positive which was partially 
non-specific. Subsequent neutralization test of this sample was negative. 
3. Mokola. 
Mokola is a rabies-related virus which has been isolated from several 
humans in Nigeria, including one child who died of a poliomyelitis-like 
illness. The virus has also been isolated from shrews in Nigeria. Anti¬ 
bodies have been found in humans, cattle, sheep, goats, swine, bats, and 
48 





Chikungunya is a member of the group A arboviruses, which belongs to 
the genus Alphavirus. Of the group A viruses six are known to exist in 
Africa: chikungunya, Middelburg, Ndumu, o'nyong nyong, Semliki Forest, 
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and Sindbis. All except Sindbis and Ndumu have been isolated in West 
Africa. Chikungunya, o'nyong nyong, and Sindbis viruses have been found 
in humans. NT antibodies have been found in human sera for Semliki Forest 
and Ndumu. However human antibodies to Middelburg have been virtually 
absent. Human infections with Semliki Forest have been documented in 
laboratory workers, although such infections have not been documented in 
nature. These viruses are transmitted by culicine and anopheline mosqui- 
52 
toes. 
Chikungunya virus has been isolated from humans in the West African 
countries of Nigeria and Senegal; it has also been isolated in East Africa 
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and South Africa. Using the HI test with a battery of group A antigens, 
it has been demonstrated that the first or "primary infection" of an ani¬ 
mal or human with a group A virus, will produce a distinctive HI pattern 
with the different antigens which is diagnostic of infection with that 
virus. The pattern of HI antibodies resulting from primary group A in¬ 
fections is "so distinctive that it is the method of choice" for doing 
surveys for this arbovirus group. HI studies have shown that chikungunya 
and "to a slightly lesser extent", o'nyong nyong are the major group A 
infections of humans in Africa. These studies imply that chikungunya is 
present all over sub-Sahara Africa, including the West African countries 
of Liberia, Guinea, Ghana, and Nigeria. Liberian chimpanzees have also 
shown the same primary infection pattern by HI test.^^ 
It must be stated that o'nyong nyong is closely related to chikungunya 
virus. Because convalescent sera from people exposed to o'nyong nyong 
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virus will protect against chikungunya virus, one cannot use the NT with 
chikungunya virus to distinguish chikungunya from o'nyong nyong. One 
reliable means of distinguishing between these two agents is by running 
serum samples in HI tests with both antigens and checking for a higher 
titer with one of them. Since this has not been done in the Liberian 
survey, one must reserve final judgment as to how many of the positive 
tests in the survey might actually be due to chikungunya and how many 
might be due to o’nyong nyong. It must be kept in mind that "group A 
agents that are shown to be closely related by HI studies, are also, as 
far as available evidence goes, closely related by CF or neutralization 
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tests." So it is with chikungunya and o’nyong nyong. Although 
o'nyong nyong has not been isolated from humans in West Africa, as is the 
case with chikungunya, this fact does not allow one the liberty of eliminat¬ 
ing the possibility that this agent is responsible for some of the positive 
serologies with chikungunya. 
As mentioned earlier, of the 165 sera in the survey, 24 sera were CF 
positive for chikungunya and 34 sera were HI positive for the same agent. 
The 24 sera which were CF positive were also HI positive. The fact that 
CF antibodies usually disappear more rapidly than HI antibodies, is the 
most likely explanation for the observation that 10 sera were HI positive 
but CF negative. 
Of the 24 sera that were positive for chikungunya by both CF and HI 
tests, eleven were selected for the NT (Chapter Two, Table 8-E). All these 
sera neutralized chikungunya virus. Six sera which were negative for chi¬ 
kungunya by both CF and HI tests, were also selected for the NT; all six 
failed to neutralize virus. One significant conclusion that can be drawn, 
is the excellent positive correlation of CF and HI test results with NT results. 
I 
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The data suggest very strongly that Liberian sera that are positive to 
chikungunya by CF and HI test, will also be positive to chikungunya by 
NT. Thus one may conclude that all of the 24 sera that are positive to 
chikungunya by both CF and HI test, would also be positive by NT. These 
24 sera constitute 15% of all the sera collected in Liberia. If one also 
includes the 10 sera which were positive by HI test but negative by CF 
test, the total of 34 sera with antibodies to chikungunya, constitutes 21% 
of all sera collected in Liberia. 
Several interesting correlations can be made between the survey pop¬ 
ulation and the serological test results. (Table 9 on following page). 
The percentage of males with antibodies to chikungunya (31%) was twice 
that of females (16%). The percentage of farmers with antibodies (52%) 
was more than three times that for health care workers (15%). The per¬ 
centage of those with antibodies at Phebe Hospital (38%) was more than 
three times that of Curran Hospital in Zorzor (11%) and more than ten 
times that of the Maternity Center in Monrovia (3%). Although these 
correlations are noteworthy, statistical analysis of the figures was not 
felt to be justified. The reason for this, is the highly biased method 
of selection in this survey, as explained in the first section of this 
chapter. Nonetheless these correlations suggest that exposure to the 
agent or agents producing antibodies to chikungunya, may be associated 
with activities more frequently undertaken by males, including farming; 
and exposure may be less frequent among health care workers. These cor¬ 
relations may also suggest a higher exposure rate in the region served 
by Phebe Hospital than in the region served by Curran Hospital. Also the 
exposure rate appears to be very low among the health care workers at the 
Maternity Center who have in general worked in that hospital for many years 




Prevalence Rates of Chikungunya Antibodies 
Characterists Number Tested Number Positive"'” Percent Positive 
Liberian Survey,Total 165 34 21% 
Sex 
Male 51 16 31% 
Female 114 18 16% 
Occupation 
Health Care Worker 104 16 15% 
Farmer 17 9 52% 
Other or Unknown 44 9 20% 
Hospital 
Phebe 37 14 38% 
Curran 35 4 11% 
ELWA 61 15 25% 
Maternity Center 32 1 3% 
Age 
<10 0 — _ 
10-19 13 4 31% 
20-29 64 10 16% 
30-39 45 4 9% 
40-49 23 8 35% 
50-59 5 2 40% 
>60 9 6 67% 
Unknown 6 1 0 0% 
''■Positive sera had CF titers >1:4 and/or HI titers _>1:10. 
results were confirmed on selected sera by NT tests. 
CF and HI test 
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must keep in mind, however, that these conclusions may not be an accurate 
reflection of the true picture, due to the skewing of the survey population, 
which was mentioned at the beginning of the Chapter. 
One last observation about chikungunya may be made by employing the 
following reasoning. If a person has antibodies to a virus, and if that 
person resided in only one location for his entire life, then most likely 
the responsible viral agent originated from the same location. Some ex¬ 
ceptions to this generalization might be: exposure to the agent during a 
sojourn away from his residence; or importation into his residential area 
of an agent, for example, by an outside visitor. However, most likely that 
agent is indigenous to the person's local area. There were a number of 
people in the Liberian survey who had antibodies to chikungunya, and who 
also claimed only one lifetime residence. The counties in which these people 
resided were: Bong (sera //22, 23, 36, 42, and 47), Loffa (sera #87, 96, and 
99), Nimba (serum #104), Grand Bassa (serum #126), and Montserrado (serum 
#169). Thus one might conclude that there is a reasonable possibility that 





Bwamba is a member of the group Bwamba, which belongs to the Bunyam- 
wera supergroup, which belongs to the genus Bunyavirus. The Bwamba group 
consists of only two viruses, Bwamba and Pongola; both have been found only 
59 
in Africa. 
Bwamba has been isolated from humans in Nigeria, Uganda, and the 
Central African Republic.^ Neutralization tests show human antibodies 
to Bwamba are widespread in Africa south of the Sahara, namely in Central, 
East, West, and South Africa.^ Isolations have not been made from lower 
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vertebrates, although NT antibodies have been found. The virus has 
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been isolated from anopheline mosquitoes. 
Pongola virus has not been isolated from humans or lower vertebrates.^ 
However NT antibodies have been found in humans from the southern African 
countries of Angola, Botswana, Mozambique, and South Africa. The virus has 
been isolated from anopheline and culicine mosquitoes from countries as far 
north as the Central African Republic, Uganda, and Ethiopia. No isolations 
have been made in West Africa.^ 
It must be emphasized that Bwamba virus and Pongola virus have much 
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serological overlap. By CF test the two viruses are related, although 
68 
they are not identical. "Due to the marked immunological overlap between 
Bwamba and Pongola viruses, the interpretation of the results of N tests is 
"69 
difficult. Nevertheless it is possible to distinguish between them by 
using CF and neutralization tests. It must be acknowledged, however, that 
the tests performed on the Liberian serum samples are not sufficient to make 
any definitive identification. 
With this in mind the results of the NT with Bwamba will be discussed 
(Chapter Two, Table 8-B). Of the eleven CF positive sera, eight were protective. 
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and three were non-protective. One possible explanation for the failure 
of these three CF positive sera to neutralize virus, is that the CF anti¬ 
bodies resulted from infection with a virus related to Bwamba which was 
not able to neutralize Bwamba. This virus might be Pongola, which need 
not elicit NT antibodies to Bwamba.^ This virus might also be an un¬ 
discovered relative. One must also consider that the end-point serum 
titer for these three sera, was 1:4, which may be too weak to be con¬ 
sidered a definitely positive CF test. One final possibility is an 
error in technique; however, adequate controls were present for both the 
CF and neutralization assays. 
Of the six CF negative sera used in the Bwamba NT, two were pro¬ 
tective, and four were non-protective. The fact that CF antibodies dis¬ 
appear more quickly than NT antibodies, is the best explanation for the 
neutralization of virus by CF negative sera. Thus the CF screening test 
which was used to screen all the Liberian samples, failed to identify a 
number of sera with NT antibodies to Bwamba, making it impossible to 
state accurately what proportion of people possessed NT antibodies to 
Bwamba. 
One last observation about Bwamba is based upon the rationale men¬ 
tioned in the discussion of chikungunya. A couple of people with NT 
antibodies to Bwamba claimed only one lifetime residence, suggesting that 
the agent responsible for these antibodies is indigenous to their local 
areas. One such area is Bong County (serum #24), and another is Loffa 




Ingwavuma is a member of the Simbu group of viruses, which belongs 
to the Bunyamwera supergroup. Nine members of the Simbu group have been 
reported in Africa: Ingwavuma, Nola, Sabo, Sango, Sathuperi, Shamonda, 
Shuni, Simbu, and Thimiri. The only one of these agents to be isolated 
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from humans, has been Shuni. This isolation was made in Nigeria. 
Besides Shuni, Simbu is the only virus of the group for which human anti¬ 
bodies have been found. All of these viruses have been isolated from 
vertebrates and/or arthropods in West Africa, except for Nola, Simbu, 
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and Thimiri. The arthropod vectors for these agents are culicine mos¬ 
quitoes and/or Culicoides flies.^ 
As mentioned above, Ingwavuma has not been isolated from man. 
Neither have human antibodies been found. Virus isolations have been 
made from several species of birds from Nigeria, Central African Republic, 
and South Africa. The virus has also been isolated from culicine mosqui¬ 
toes from the Central African Republic and South Africa.^ 
The Liberian survey yielded no evidence to suggest the occurrence of 
Ingwavuma in humans (Chapter Two, Table 8-D). Six serum samples were 
weakly positive by HI test, but they were all negative by NT. While these 
weakly positive HI tests may imply exposure to a relative of Ingwavuma, 
one must keep in mind that HI titers of 1:10 are of questionable signifi- 
76 
cance and should not be assumed to be clear-cut positives. 
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7. Bunyamwera Group Members: Ilesha and Bunyamwera. 
Ilesha and Bunyamwera are members of the Bunyamwera group which be¬ 
longs to the Bunyamwera supergroup. Four viruses of the Bunyamwera group 
have been found in Africa: Birao, Bunyamwera, Germiston, and Ilesha. 
Arthropod vectors for these viruses are either anopheline or culicine 
, 77 
mosquitoes. 
Birao has been isolated only from mosquitoes in the Central African 
Republic. Significant serological survey work with Birao has not been 
done.^ 
Bunyamwera has been isolated from humans in Nigeria, Uganda, Kenya, 
79 
and South Africa. Virus isolations and serological surveys indicate 
Of) 
that Bunyamwera virus is widespread throughout Africa. 
Ilesha virus has been isolated from humans in Nigeria, Cameroun, 
Central African Republic, and Uganda. NT antibodies have been found in 
humans but not in any other vertebrates. These antibodies came from 
81 
people in Nigeria, Uganda, and the West Nile region. 
Germiston has been isolated in several countries of eastern and 
southern Africa, primarily from mosquitoes and hamsters. NT antibodies 
have been found in humans and lower vertebrates in the same regions of 
Africa. Although human infections with Germiston have occurred as a 
result of laboratory exposure, no naturally occurring human infections 
82 
have been documented. 
Bunyamwera, Ilesha, and Germiston are serologically interrelated 
in a complicated manner. By CF test Ilesha is more closely related to 
Bunyamwera than to most other group members, while Germiston is quite 
8 3 
distinct from all other group members. 
By HI test Germiston is closer to Bunyamwera virus than to other 




tain HI antibodies to not only Bunyamwera but also to Ilesha. One 
means of resolving this overlapping of HI antibodies, has been to run 
each serum sample in HI tests with each of the three antigens—Germiston, 
Ilesha, and Bunyamwera. With those sera in which the titer for one of 
these three antigens was clearly higher than the titers for the other 
two antigens, a presumptive diagnosis could be made. However with those 
sera in which the titers for two or all three of these antigens were al¬ 
most equal, no presumptive diagnosis was possible. "In extensive HI 
studies with Bunyamwera group antigens—and sera from West Africa, the 
Sudan, and Ethiopia—positive reactions were quite common.In most in¬ 
stances the HI patterns suggested previous infection with either Germiston 
of Ilesha virus. In only relatively few instances were the titers obtained 
with a Bunyamwera antigen higher than those observed with the other two— 
indicating that infections with Ilesha and Germiston viruses are far more 
"86 
common in these regions than infections with Bunyamwera. These studies 
suggest that Ilesha is probably responsible for human infections in Liberia, 
87 
as well as Ghana, Nigeria, and Ethiopia. 
O O 
By NT there is little overlap between Ilesha and Bunyamwera. However 
there is a very marked overlap between Germiston and Bunyamwera. Casals 
has demonstrated that mice which had been previously exposed to Bunyamwera 
virus were almost entirely resistant to intraperitoneal challenge with 
~ _ 89 
Germiston. 
In conclusion it can be seen that the Bunyamwera group viruses are 
serologically interrelated in a complex manner. Since HI tests were not 
done on the Liberian sera with Germiston to complement the HI tests done 
with Bunyamwera and Ilesha, no presumptive diagnosis can be made on the 
basis of HI titer comparison. 

7a. Ilesha. 
The striking finding in the serological test results on Ilesha is 
the wide discrepancy between the HI and NT test results (Chapter Two, 
Table 8-C). Only 11 sera were found to be positive by HI test, all 
with a low titer of 1:10. In the NT test 9 of these 11 were protective 
and one was a partially protective. Thus most of the HI positive sera 
were positive by NT test. The surprising finding is that 5 out of 6 of 
the HI negative samples were also protectors. Thus most of the HI neg¬ 
ative sera were also positive by NT test. It appears therefore that the 
proportion of NT positive sera is the same for HI positive and HI nega¬ 
tive sera. 
There are several possible explanations for these serological test 
results. One is that there truly is a high incidence of NT antibodies 
to Ilesha among the population of Liberia. If this is the case, then 
one must explain why HI antibodies were found in only 7% of the Liberian 
sera. Even if one acknowledges that some of the sera may have lost their 
HI antibodies due to the passage of time, it is highly unlikely that such 
a large proportion of the population would have lost their HI antibodies. 
Another discrepancy is the total absence of high HI titers, which one 
would anticipate, if most of the population truly have NT antibodies. 
As previously mentioned, HI titers of 1:10 are generally of questionable 
significance. It has been shown that humans can generate high antibody 
90 
titers to Ilesha. So one can exclude the inability of humans to form 
highly antibody titers. 
A second possible explanation for this discrepancy, is that there 
may be a non-specific neutralizing substance in the sera.91 Such a sub¬ 
stance could cause protection in a NT test, regardless of whether or not 
the serum contains true NT antibodies. A third explanation might be that 
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the HI technique was subject to error. This seems unlikely since HA 
titrations to determine the number of units of antigen present, were 
valid. Other controls were also valid. It is also possible that the 
Ilesha antigen is insensitive, i.e., is difficult to inhibit. One 
final possibility might be the presence in Liberia of a relative of 
Ilesha which has strong cross-over by NT test with very little cross¬ 




Of the 13 HI positive sera out of the 165 samples in the survey, only 
two were protective by NT test; two were partially protective; and nine 
were non-protective (Chapter Two, Table 8-F). Of the six HI negative sera 
in the NT test, one was protective; one was partially protective; and four 
were non-protective. One very noticeable observation from these results, 
is that the ratio of protectors, partial protectors, and non-protectors, is 
almost the same for the HI negative and HI positive sera. 
One might recall that in the discussion of Ilesha the ratio of pro¬ 
tectors to non-protectors was also almost the same for the HI positive and 
HI negative sera. Similar to Ilesha, one possible explanation might be 
that all of the protectors and partial protectors were due to infection 
with Bunyamwera or a related group member. One might explain the fact that 
HI negative sera were protectors, as a consequence of the more rapid disap¬ 
pearance of NT antibodies. This might also be explained by a related virus 
which has cross-over of NT antibodies without much cross-over of HI anti¬ 
bodies. One might explain the fact that HI positive sera were non-protec- 
tors, as resulting from exposure to a virus related to Bunyamwera which 
would elicit HI antibodies to Bunyamwera but not NT antibodies. As with 
Ilesha a second explanation might be the presence of a non-specific neu¬ 
tralizing substance. A final explanation might be that the HI technique 
was subject to error. This seems unlikely, since HA titrations and other 
controls were valid. 
One conclusion that might be drawn is that in the context of Liberia, 
the HI test for Bunyamwera is not very adequate for predicting how a serum 
sample will react in a NT test for Bunyamwera. If one eliminates those 
sera with an HI titer of <1:10 as being of too low a titer to entertain as 
definitely positive, there are still sera which are negative by NT test 
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with HI titers of 1:20 (sera //23, 38, 42, and 139) and 1:40 (serum #24) . 
The highest titer observed by HI test was 1:80 (serum #153), and this 
serum did turn out to be positive by NT test. One however cannot use 
this one serum sample to make a general statement that an HI titer of 
1:80 or greater will correlate well with NT test positivity. One might 
have anticipated the possibility of a poor correlation between Bunyam- 
wera HI and NT tests, since this has been observed previously with sera 
from Mozambique. The occurrence of viruses related to Bunyamwera 
could result in sera which would give HI positive but NT negative re¬ 
sults. One might recollect that presumptive positives for Germiston 
and Ilesha have been shown to be more prevalent in Africa than presumptive 
serological positives for Bunyainwera. These other two agents can elicit 
Q Q 
HI antibodies to Bunyamwera. One must also bear in mind that a positive 
NT test for Bunyamwera does not mean that Bunyamwera was the responsible 
agent: "Until more extensive studies have been made, the interpretation 





8. Group B Arboviruses: Dengue II, West Nile, Yellow Fever, and Zika. 
95 
GroupB arboviruses belong to the genus Flavivirus. There are a 
96 
total of 17 group B viruses in Africa. Group B is divided into three 
97 
subgroups, based upon the arthropod vectors involved. 
The largest of the three subgroups is concerned with those viruses 
transmitted by mosquito vectors; these viruses have seldom been isolated 
from other arthropods. Most of these agents can cause disease in man, 
and they often do so in large outbreaks. Isolates have been obtained 
most commonly from man and birds, although isolations have been made 
98 
from other categories of vertebrates. African members of this sub¬ 
group include: Banzi, Bouboui, dengue I, dengue II, Ntaya, Spondweni, 
Uganda S, Usutu, Wesselsbron, West Nile, yellow fever, and Zika. All 
have been isolated from humans, except Bouboui, Ntaya, Uganda S, and 
99 
Usutu. Human serological tests have been positive for all of these 
except Usutu. Except for Banzi and Ntaya, all of these viruses have 
been isolated in West Africa. Of the four group B agents used in the 
Liberian survey, dengue II, yellow fever and Zika have been isolated 
from humans in West Africa. The West African isolates of West Nile do 
100 
not include any from humans. 
The second subgroup concerns group B viruses that are carried by 
ticks. Only one such virus has been isolated in Africa, namely Kadam 
It has not been isolated from humans or other vertebrates. The tick is 
the only animal from which the virus has been isolated. It has been 
102 
isolated only in Uganda. 
The final subgroup of group B viruses consists of those agents for 
r 103 
which an arthropod vector has not been identified. Four members of 
this subgroup have been isolated in Africa: Dakar Bat, Entebbe Bat, 




positive human serologies have been found only for Dakar Bat virus in 
Senegal and for Saboya virus in Sierra Leone. All have been isolated 
from bats or rodents. All except Entebbe Bat virus have been isolated 
T7 A-F • 105 in West Africa. 
At this point it is appropriate to discuss the interpretation of 
group B serological rest results. To be sure, "the most definitive 
diagnosis of an infection is made if a virus is isolated and identified. 
Often, however, the diagnostician is confined to the study of pairs of 
sera taken at different times after the onset of illness. Even less 
definitive than the above two situations, is the study of an unpaired 
serum sample taken at a time during which the patient may or may not 
have been ill, as is the case with the Liberian survey samples. 
Besides the limitation imposed by the use of unpaired sera, a 
second diagnostic limitation on the Liberian survey stems from the 
notorious tendency of group B viruses for marked immunological overlap, 
which often times renders serological identification absolutely impossible. 
This is true especially of "secondary infections." A "secondary infection" 
may be defined as the second infection of a subject with agents from an 
arbovirus group, the agents responsible for these two infections being 
different from one another. A person who has had a secondary infection 
with group B viruses will therefore have been exposed to two different 
group B viruses. The hallmark of a group B secondary infection, is that 
the serum is widely cross-reactive, possessing significant antibody levels 
to many group B agents. Heterologous antibody levels may even exceed homo- 
logous antibody levels. There is nearly complete absence of specificity 
of HI and sometimes of CF antibodies, and the presence of heterologous NT 
antibodies may be quite marked. Therefore, after a secondary infection,it 
is extremely difficult, if not impossible, to make any specific serological 
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diagnosis. It is therefore essential when doing serological survey 
work in a region where several group B agents are known to exist, to 
employ several group B antigens by CF or HI tests to determine whether 
the serum demonstrates a secondary infection. If such is the case, the 
only permissible conclusion is that the subject has been exposed to 
group B viruses; specific diagnosis of the responsible agents is not 
possible. Since Liberia is in a region where numerous group B agents 
are known to be present, four group B agents were employed in the HI 
tests with the serum samples, in order to identify secondary infections. 
It is still possible, however, to draw some diagnostic conclusions 
about infections with group B viruses, since identification is possible 
with respect to "primary infections." A "primary infection" may be de¬ 
fined as the first infection of a subject with an agent from an arbovirus 
group. A person who has had a primary infection with a group B virus 
will therefore have been exposed only once to only one group B virus. 
To be sure, the preferable way of diagnosing a primary infection, is to 
have paired sera taken at different times after the onset of illness and 
to demonstrate the de novo appearance of group B antibodies. However it 
is still possible to use an unpaired serum sample to identify group B 
primary infections and make a presumptive diagnosis of the responsible 
agent. The reason for this is that after a primary infection with a group 
B virus, the HI antibody pattern is characteristic for each virus and is 
112 
diagnostic of previous infection with that agent. With this pattern 
there is often the production of antibodies to other group B agents. The 
highest titer is obtained with homologous antibodies, and "the hetero¬ 
logous titers are higher to closely related viruses and lower to more dis- 
114 
tantly related agents." Thus in order to identify the patterns of 
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primary reactions it is necessary to employ a number of group B antigens 
by CF or HI test.^"* A diagnosis by HI test of a primary infection and 
of the agent responsible can be made if there is a serum titer of _>1:20 
and 8 units of antigen "with a fourfold or greater difference between it 
and the highest titer given by the serum against another antigen of the 
same group.It must be mentioned that while each group B agent has 
its own characteristic pattern for primary infection, this pattern may 
not be very commonly observed in West Africa, because of the presence of 
many group B agents,"... in the majority of localities studied a very high 
incidence, approaching 100% in many cases, of group B antibodies occurred. 
In only a relatively few cases could a diagnosis of specific infecting 
,,117 
virus be made from the HI pattern. 
A comment upon the usefulness of neutralization tests with group B 
viruses is now appropriate. It should be stated that the NT is only diag¬ 
nostic in situations shown to be primary infections by HI tests. "It is 
our experience that the results of all group B N tests must be interpreted 
with extreme caution, unless the HI pattern is typical. As the predominant 
HI pattern in tropical Africa is one typical of multiple infections it 
follows that most N tests must be interpreted with great care. A positive 
N test result with a given group B agent is consistent with, but by no 
means proof of, infection with that agent. These criticisms apply to all 
antibody survey using the N test in the Sudan and other tropical African 
,,118 
countries. The reason for the limited diagnostic capability of the NT 
in situations other than primary infection pattern by HI test, is the marked 
. . . ^ 119 
cross-neutralization among group B agents, even after primary infections: 
"...an infection with any group B virus is followed by the development of 
neutralizing antibodies not only to the infecting agent but also to a greater 
or lesser extent to many (possibly all) other group B viruses. The extent to 
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which these heterologous antibodies are developed is largely unknown and, 
consequently, in antibody surveys utilizing the N test only, the results 
120 
are often difficult or impossible to interpret." 
The discussion of the Liberian serological test results with the 
four group B members will be limited primarily to Zika and yellow fever. 
Zika was the only group B member to be run by NT, and it has a fairly 
distinct HI pattern for primary infections. Yellow fever is the most 
famous and the most thoroughly studied arbovirus. In West Africa primary 
infection patterns with West Nile have seldom been seen, although group B 
antibodies are quite prevalent. Instead of primary infection patterns, HI 
antibodies to West Nile have almost always been part of patterns consistent 
with group B secondary infections. The NT with West Nile cannot be trusted 
to be diagnostic because, "In all the countries of Africa—with the possible 
exception of Egypt—other group B viruses are prevalent.Many of the positive 
N test results with the WN virus may in fact be due to overlap with other 
121 
group B agents." A similar statement can be made about the N test for 
122 




The following quote will serve as an adequate introduction for the 
discussion of the Liberian serological test results for Zika. "In ex¬ 
tensive HI studies with sera from West Africa, it was found that the 
great majority of sera gave a pattern non-diagnostic of a Zika infection. 
However in a small proportion of sera, the HI patterns were diagnostic. 
These were observed mainly in children or at times in adults in regions 
where the overall incidence of group B antibodies was low. Confirmation 
of the diagnosis made by HI studies was obtained by the use of N test 
with Zika virus, indicating a very close correspondence between the two 
tests. In the antibody survey studies in the RFVL-NY, using HI techniques 
and sera from Africa, we have good evidence that human infections are pre¬ 
valent in the various countries of West Africa (Nigeria, Ghana, Liberia, 
123 
and the Cameroons)..." 
Upon comparison of Zika HI test results with Zika NT results in the 
Liberian survey (Chapter Two, Table 8-A), one notices that many of the 
sera which were HI positive, were NT negative. Half of the sera which 
were HI positive to Zika plus one or two other group B antigens, turned 
out to be negative by NT. While the neutralization tests for Zika were 
positive in the other half of these sera, one cannot state that the sero¬ 
logical tests are diagnostic of Zika infection, because for some of these 
sera the HI patterns are not consistent with a primary infection. As pre¬ 
viously mentioned, an HI pattern characteristic of a primary infection is 
necessary for serologic diagnosis with group B members. However one of 
these sera does fit the criteria for a primary infection pattern by HI test, 
since the titer for Zika is more than fourfold higher than the titers for 
the other antigens (serum //103). Thus with this serumsample, one may make a 
presumptive diagnosis of Zika infection. 
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Also tested were eight broad group B sera which were HI positive to 
all four of the group B antigens; such sera are characteristic of secondary 
or multiple infections with group B viruses. Very surprisingly all eight 
sera failed to neutralize Zika. To be sure, this failure of broad group B 
sera to neutralize Zika, cannot be construed to be a universal phenomenon 
of all sera with broad group B reactions. However the above results demon— 
s^rates that positivity by HI test for Zika, does not necessarily imply 
positivity by NT for Zika. It is noteworthy that with these broad group B 
sera, the HI titers for Zika were as high as 1:320 (serum //20); yet neutra¬ 
lization did not occur. 
Another observation with Zika concerns those sera which were HI positive 
for Zika but were HI negative to all other group B antigens. These sera 
belong to an HI pattern which is characteristic of primary infections with 
12b 
Zika. All of these sera neutralized Zika virus (Chapter Two, Table 8-A). 
As mentioned earlier in the discussion, a primary infection pattern by HI 
test, confirmed by NT, may be considered adequate to make a presumptive 
diagnosis of infection with a particular group B agent. One may therefore 
consider that all sera in the survey which fall into the same HI pattern, 
125 
represent Zika infections. A total of six sera in the survey with an 
HI titer of 1:10 or higher, fit this pattern (Chapter Two, Table 6-A). Two 
have titers of 1:10 (sera #11 and 168). To be sure, there is justification 
for disregarding these sera with titers of 1:10 as inconclusive, because of 
the low titer. However the titers of the other four are: 1:20 (serum 
#106), 1:40 (serum #134), 1:80 (serum #150), and 1:160 (serum #81). 
One might comment about the occurrence of a similar behavior with other 
group B members. Primary infections with other group B members are mani¬ 
fested by an HI pattern with antibodies elicited only for that given virus 
127 
but for no others. A similar primary infection pattern is known to exist 
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for yellow fever and for the 17D strain used for yellow fever immunization. 
In the Liberian survey there were nine sera that were positive only to 
yellow fever with an HI titer of 1:20 or higher, but were negative by HI 
test to the three other group B antigens (Chapter Two, Table 6-A). One may 
thus assume that these nine sera represent actual cases of yellow fever or 
immunizations with the 17D strain. In the Liberian survey similar HI test 
results were not observed with dengue II or West Nile (Chapter Two, Table 
6-A). 
One other statement about Zika pertains to reasoning mentioned earlier 
in this Chapter to support the idea that if a person spends his entire life 
residing in one locality, any viral agent to which he has been exposed, 
most likely originated in the locality. One may state therefore that Zika 
most likely occurs in Montserrado County (sera 7/103 and 150) . 
In summary it may be safely concluded that on the basis of this survey, 
Zika virus is present in Liberia. This is consistent with previous sero¬ 
logical surveys of Liberia. The exact proportion of the survey population 
exposed to Zika, cannot be determined, because except for primary infections, 
one cannot with reasonable certainty use HI or neutralization test results 
to arrive at a presumptive serological diagnosis. 

8b. Yellow Fever. 
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The following quote will serve as an appropriate introduction to the 
discussion of yellow fever. "Our studies with sera from West Africa in¬ 
dicated that in the majority of localities studied a very high incidence, 
approaching 100% in many cases, of group B antibodies occurred. In only 
a relatively few cases could a diagnosis of specific infecting virus be 
made from the HI pattern. These were observed chiefly in children and in 
a few places in adults where the overall group B incidence was low. These 
studies indicated that YF infections were prevalent in Liberia, Ghana, 
Nigeria, and the Cameroons, the countries from which sera were obtained 
129 
for this survey." 
Because yellow fever immunization histories were not obtained from 
those surveyed, the scope of worthwhile investigation into yellow fever 
with the Liberian sera, was felt to be somewhat limited. As mentioned in 
the preceding paragraph, serological studies with Liberian sera have re¬ 
vealed HI patterns diagnostic of yellow fever. During the previous decade 
human cases of yellow fever in Liberia were diagnosed on the basis of 
clinical evidence and post-mortem examination. At that time immuniza¬ 
tion campaigns were done. To be sure, all of the 10 foreigners in the 
present Liberian survey, and most certainly, some nationals have had immuni¬ 
zation against yellow fever. Without immunization histories it is impossible 
to differentiate between HI and NT antibodies resulting from actual infection 
with yellow fever and antibodies resulting from immunization with the 17D 
strain. For this reason neutralization tests with this virus were not per¬ 
formed. 
The subject of primary infection patterns for yellow fever by HI tests, 
has already been mentioned above in the discussion of Zika. One particular 
aspect of these primary infections, concerns sera possessing HI titers of 1:80 
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or greater. Such high titers occur either after immunization with the 17D 
strain in which case these high antibody levels persist only for a brief 
period of several weeks, or after an actual case of yellow fever in which 
case this high titer will often persist for a longer period of years. 
Only one serum sample in the survey fits these criteria, having a titer of 
1:80 (serum #181). This person was a 28 year-old nurse at the Maternity 
Center who had lived for 19 years in Sinoe County before coming to Monser— 
rado County. Since she is in a position in which recfent immunization may 
have been possible, it cannot be discerned without a vaccination history, 
what is the cause of her high titer. 
One last comment about yellow fever concerns one individual who was 
HI negative to yellow fever but who was certainly immunized (serum #72). 
This person is an American who came to Liberia six yeara ago. Since 
yellow fever immunization is required to enter Liberia, she most defi— 
nitely received the 17D vaccine. To be sure, HI antibodies to yellow 
fever may have been detectable in the past; and they may have dropped 
below detectable levels with the passage of time. However another pos- 
®ibility is the established observation that HI antibodies sometimes 
132 
never develop after immunization. 
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8c. Other Group B HI Reactions. 
One comment might be made about the broad group B sera which were HI 
positive to all four of the group B antigens (Chapter Two, Table 6-C). 
As previously mentioned, such sera are characteristic of secondary or 
multiple infections with group B viruses. Of the 18 broad group B sera 
in the survey, 16 were HI positive to Bunyamwera. Since there is no 
immunologic cross-over between group B viruses and Bunyamwera supergroup 
viruses, a possible explanation for this observation is that the people 
were resident in localities (rural, forest, semi-urban) in which vertebrate 
hosts and invertebrate vectors of several arboviruses were established. 
With many species of mosquitoes in such localities, some of which have 
been shown to be virus vectors, the possibility of acquiring infections 
by viruses of each of several groups will be increased. 
One last comment in the discussion concerns the overall incidence of 
group B HI antibodies. As mentioned in the previous chapter, 57% of those 
surveyed possessed HI antibodies to one or more of the four group B members. 
While this constitutes a majority of the people in the survey, it does not 
approach the incidence of 100% which has been observed in many parts of 
West Africa. One must, however, refrain from concluding that this percentage 
is an accurate representation of the Liberian population as a whole. One 
must bear in mind that the survey population is skewed along certain lines. 
One must also remember that immunization with the 17D strain of yellow fever 





Diluent for all tests consisted of veronal buffer diluted 1:5 with 
demineralized distilled water, having a pH of 7.3-7.4. 
The hemolytic system consisted of an equivolume mixture of Baltimore 
Biologic Lab hemolysin held at a 1:400 dilution for 15 min prior to mixing 
and of Baltimore Biologic Lab sheep red blood cells held at a 2 1/2% dilu¬ 
tion for 15 min prior to mixing. Prior to use the hemolytic system was 
allowed to stand for 15 min. 
Complement consisted of Flow Laboratories lyophilized guinea pig 
complement which was rehydrated with the accompanying prepackaged solvent. 
This was then diluted 1:55 for the titration of complement. 
Serum samples at dilutions of 1:4 and 1:8 were placed in a water bath 
at 60°C for 20 min to inactivate complement and non-specific reactants. 
Further serum dilutions were made from these. The same procedure was used 
to inactivate the immune ascitic fluid which served to confirm the identity 
of antigen in each CF test. 
A. Titration of Complement. 
A series of complement dilutions was prepared in 13x100mm test tubes, 
constituting the master set of complement dilutions which was used in the 
preliminary and final titrations of complement: 
Tube # 123456789 
C' 1:55 in cc 1.6 1.4 1.2 1.0 0.8 0.7 0.6 0.4 0.2 
VB 1:5 in cc 1.4 1.6 1.8 2.0 2.2 2.3 2.4 2.6 2.8 
Preliminary complement titration consisted of a series of 12x75mm test 
tubes, one for each master tube. To each tube was added: 0.3cc of the cor- 
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responding master dilution, O.lcc of diluent, and 0.2cc of the hemolytic 
system. The tubes were shaken vigorously, incubated in' a water bath at 
37°C for 30 min with occasional shaking, and then allowed to stand at 
room temperature for one hour before reading. The smallest amount of 
complement causing complete hemolysis was considered as one unit of 
complement. Since the CF test proper required 2 units of complement per 
0.2cc, the 1:55 dilution of complement was adjusted by further dilution, 
if necessary, to make 2 units/0.2cc. 
B. Complement-Fixation Test Proper. 
The basic test consisted of a 6 drop/well system, using 0.025cc 
drops into 96-well plastic trays. The first drop was serum in a dilution 
of 1:4 or varying two-fold dilutions thereof. The next two drops con¬ 
sisted of the 2 unit complement. The fourth drop consisted of antigen 
in varying dilutions. After addition of these 4 drops/well the trays 
were covered with celluloid sheets to prevent evaporation and stored 
overnight (12-18 hours) at 4°C. On the following day the trays were 
allowed to stand at room temperature for 15 min, and then the final two 
drops, the hemolytic system, were added with vigorous shaking on a vi¬ 
brator. The trays were again covered with celluloid and incubated for 
30 min at 37°C with one vigorous shaking after 10 min. The trays were 
then allowed to sit at room temperature for several hours before reading. 
Results were recorded as follows: complete hemolysis "0"; no hemolysis 
"4"; intermediate values of "+", "1", "2", "3". 
The tests also included the following controls: 
1) Assay of each human serum with the fourth drop in the system 
being normal mouse brain or veronal buffer. These controls served to 
screen out anticomplementary and mouse tissue reactive sera. 
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2) Final titration of complement in which the first three drops 
of the system were the master dilutions of complement, and the fourth was 
diluent. This served to monitor any change of the strength of complement 
overnight. 
3) Assay of the antigen at varying dilutions (usually 4-fold from 
1:4 up to 1:256) with varying dilutions (usually 2-fold from 1:4 up to 
1:128) of mouse immune ascitic fluid specific for that antigen. This was 
done to confirm the identity of the antigen. Controls of normal mouse 
brain and veronal buffer were also used to insure that neither the antigen 





Goose erythrocytes for the test were collected in acid-citrate- 
dextrose, washed four times with a dextrose-gelatin-veronal solution, 
and thereafter standardized using a spectrophotometer by making a dilu¬ 
tion with 0.15M NaCl as diluent to give an optical density between 0.43 
and 0.47 at 490mu. To prevent microbial contamination merthiolate was 
added 1:10,000 by volume. 
Solutions used in the HI test were: a)borate—saline at pH 9 
(0.05M borate-0.12 NaCl, abbreviated BS); b) BS at pH 9 with 0.4% 
bovine plasma albumin (abbreviated BS-BPA); c) viral adjusting diluents 
(abbreviated VAD), consisting of buffers of various pH values from 5.9 
to 7.0 prepated from varied proportions of mono—and di—basic sodium 
phosphate. 
Preparation of Liberian serum samples involved first extraction with 
kaolin to remove nonspecific inhibitors of hemagglutination and secondly 
washing with goose erythrocytes to remove any natural agglutinins. For 
the kaolin extraction, 0.5cc of serum was placed in a 13x100mm test tube, 
to which was added 2.0cc of BS at pH 9 and then 2.5cc of a 25% suspension 
of acid—washed kaolin. The mixture was kept at room temperature for 20 min 
with occasional shaking, and then it was centrifuged at 2500 rpm x 20 min 
at 4°C. Subsequently O.lcc of packed goose erythrocytes (packed by centri¬ 
fugation of the standardized goose erythrocytes at 1500 rpm x 10-15 min at 
4 C) was added to the supernatant, following which the test tube was stop¬ 
pered and shaken gently. The tube was allowed to stand in an ice bath with 
occasional shaking for 20 min; and then it was centrifuged at 1500 rpm x 10 
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min at 4°C. The supernatant was pipetted off and stored at -20°C. This 
serum was considered 1:10 dilution BS at pH 9 
Tests involved use of an automatic calibrated pipette to add aliquots 
of antigen, serum, solution, or erythrocytes into plastic trays containing 
96 wells. A microtest was used as much as possible in order to conserve 
these ingredients. While the remaining description pertains to the micro¬ 
test, the macrotest was done similarly but with 8 times more volume per 
aliquot, e.g., 0.2cc as opposed to 0.025cc. 
A. Hemagglutination Test. 
HA tests were done on each antigen in order to: 1) determine optimal 
pH for hemagglutination and 2) determine the titer of hemagglutination at 
optimal pH. 
Lyophilized antigen was rehydrated with sterile water and diluted 1:5 
with BS-BPA. This was allowed to stand overnight at 4°C to allow for dis¬ 
persion of aggregates. 
On the following day 0.025cc of antigen was placed into the first well 
of a row of 12 wells, each filled with 0.025cc of BS-BPA. The antigen was 
then serially diluted two-fold from 1:10 up to 1:5120. The twelfth well in 
the row was left as a control and was not used to dilute the antigen. The 
above procedure was repeated for as many rows as values of pH which were 
tested to determine the pH optimum. Values assayed ran from 5.9 to 7.0 in 
increments of 0.1. For any given antigen the values assayed were restricted 
to those of its characteristic pH range. To each row was then added the 
goose erythrocyte preparation diluted 1:24 with VAD of the proper pH. The 
test was allowed to stand at room temperature for several hours before 
reading. Hemagglutination was read as: "complete" if a uniform layer of 
red cells was present on the bottom of the well; "absent" if a small 
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centrally-located button of red cells was present; "partial" if the pattern 
was between that of complete and that of absent; "trace" if the button was 
not quite complete or centrally-located. 
The pH value which gave complete hemagglutination at the highest titer 
was then chosen as the pH for the HI test, and the titer was then taken as 
the unit antigen. The control well at each pH served to insure that hemag¬ 
glutination properties were absent from the goose cell-VAD mixture, as well 
as from the BS-BPA. 
B. Hemagglutination-Inhibition Test. 
Each HI test began with a preliminary HA test. A solution of antigen 
at a concentration 16 times that of the previously determined unit antigen 
was serially diluted two-fold, beginning at 1:2 up to 1:128; and the HA test 
was then done at optimal pH. If the highest titer showing complete hemag¬ 
glutination was 1:8 or 1:16, it meant that the solution used for the serial 
dilutions contained 4 or 8 units of antigen, respectively, when diluted 1:2; 
and the HI test could be commenced using this solution. If the endpoint was 
more than 1:16 or less than 1:8, the solution was diluted or concentrated, 
respectively, to obtain the 4 to 8 units of antigen needed for the HI test. 
In the actual HI test the kaolin-extracted, erythrocyte-washed serum 
was serially diluted two-fold beginning at 1:10 with BS-BPA as diluent. To 
each well an equal volume (0.025cc) of the 4-8 unit antigen was added. For 
each serum sample a control well of 0.025cc of serum without antigen was in¬ 
cluded. The trays were covered with a celluloid sheet to prevent evaporation 
and allowed to stand overnight (approx. 18 hours) at 4°C. 
A small amount of the 4-8 unit antigen was kept in a test tube overnight 
at 4°C; and on the following day it was used in a final HA test executed in 
the same manner as the preliminary HA test. The purpose of this final HA test 
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was to ascertain whether the strength of the antigen in the HI test might 
have changed overnight. 
After refrigeration the HI test was completed by the addition to each 
well of 0.05cc of the goose erythrocyte preparation diluted 1:24 with VAD 
of the optimal pH. Both the final HA test and the HI test were allowed to 
stand for several hours at room temperature before reading. For each serum 
sample the highest titer giving complete absence or '’inhibition" of hemag¬ 
glutination was recorded. If the number of units of antigen present in the 
final HA test was not 8, the HI titers for all the sera were corrected to 
correspond to the titers which would have been present had the HI test been 
done with 8 units of antigen. For instance, if the HA test showed 2 units 
of antigen, the serum titer was multiplied by 1/4. These corrected titers 
were then recorded by the number of the well corresponding to that titer: 
Well # 12345 6 7 8 
Titer 1:10 1:20 1:40 1:80 1:160 1:320 1:640 1:1280 
The control well for each serum sample was checked to insure that there were 





A. Preparation of Virus. 
Each rehydrated virus was titrated in suckling mice; and the brains 
were harvested to prepare a wet pool of virus which, after being titrated, 
was used in the NT proper. The purpose of the wet pool was to boost the 
infective titer or LD^ of each virus and also to eliminate the mass of 
inactivated virus particles which accumulated in the process of lyophili- 
zation and which can divert serum antibodies from neutralizing active in¬ 
fectious virus particles and thereby give erroneous results. Methods for 
titration, for preparation of the wet pool, and for calculation of the LD^q 
are explained below. 
Initial titrations with rehydrated YARD lyophilized virus, were done 
using 0.75% bpa (bovine plasma albumin diluted with 0.05M phosphate buffered 
_ o —4 
saline at pH 7.2) to make 10-fold dilutions of virus from 10 or 10 up to 
-9 -10 
10 or 10 . These dilutions were placed in an ice bath and then injected 
in approximately 0.02cc amounts via intracerebral route into randomized 2- 
and 3-day-old mice, numbering 8 per litter. The mice were checked daily for 
two weeks for: sickness, paralysis, death, or absence. The LD^q was sub¬ 
sequently calculated. 
For preparation of the wet pool four paralyzed mice from each virus were 
frozen at -60°C and subsequently thawed, following which their brains were: 
harvested, suspended in 8cc of 7.5% bpa, and homogenized with a glass homo- 
genizer precooled to -20°C. The homogenate was then spun at 10,000 rpm x 45 
min at 4°C. The homogenate was pipetted off and constituted an approx. 1:10 
dilution of virus known as the wet pool. Part of this wet pool was used im- 
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mediately without prior freezing in a final titration while the remainder 
was stored at -60°C in aliquots of approximately lcc each. 
The LDf-Q constitutes the theoretical concentration which will kill 
50% of inoculated subjects. The first step in its calculation involves 
using the titration to determine at each dilution, both the cumulative 
survivors from all lower dilutions and the cumulative deaths from all 
higher dilutions. The exponential integer for the was contained in 
the highest dilution at which the cumulative deaths outnumbered the cumu¬ 
lative survivors. The exponential fraction for the LD^-q was determined 
by the following formula: 
( A — B ) ( C + D ) 
2 ( AD —BC ) 
in which 
A-cumulative deaths at highest dilution at which deaths outnumbered 
cumulative survivors. 
B=cumulative survivors at highest dilution at which cumulative deaths 
outnumber cumulative survivors. 
C=sumulative deaths at lowest dilution at which cumulative survivors 
outnumber cumulative deaths. 
D=cumulative survivors at lowest dilution at which cumulative survivors 
outnumber cumulative deaths. 




Deaths Survivors Cum. Deaths 
from all Higher 
Dilutions 
Cum. Survivors 
from all Lower 
Dilutions 
10“ 3 8 0 49 0 
io:f 8 0 41 0 
10 8 0 33 0 
10-6 8 0 25 0 
10’s 
8 0 17 0 
10'? 6 2 9 “A 2=B 
10" 9 3 5 3=C 7=D 
10“10 0 8 0 15 
10"8=the highest dilution at which cumulative deaths outnumber cumulative 
survivors and thus contains the exponential integer for the LD,_q 
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The exponential fraction = 
( A — B ) ( C + D ) ( 9 — 2 ) (10) 70 




B. Neutralization Test 
The NT proper involved using the thawed wet pool with 0.75% bpa as 
diluent to make a concentration of virus 125 x the LD^q and then adding 
it in 0.2cc amounts to 0.2cc of each serum sample. The samples were then 
incubated in a water bath at 37°C for one hour, following which they were 
kept in an ice bath during the course of inoculation. Each virus-serum 
mixture was injected in a dose of approximately 0.02cc into randomized 
2-, 2-, 4-, or 5-day-old mice, numbering 8 per litter. The mice were 
checked daily for two weeks for: sickness, paralysis, death or absence. 
The completed NT for each virus consisted of five parts: 
these were divided into strongly and weakly positive sera. 
2) 125 LD^q of virus + CF or HI negative sera for that virus. 
a) Sometimes the test included sera positive for 
other viruses of the same group, e.g., Zika negative 
but broad Group B positive, when doing NT for Zika. 
b) Each test included sera which were CF or HI positive 
for antigens outside of the group, e.g., Ingwavuma 
negative but chikungunya positive when doing NT for 
Ingwavuma. 
c) Each test included sera negative to all viruses assayed 
by CF or HI. 
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3) 123 LD5q of virus + mouse immune ascitic fluid for that 
virus. 
4) 125 LD °f virus + normal mouse ascitic fluid. 
5) A titration of virus in 10-fold dilutions with 0.75% 
bpa as diluent, beginning at 125 LD and ending at 
0.0125 LD . 
For example, Bwamba: LD,-q=10 * . 
Dilutions were: 10-3*8, 10 ^'8, 10-5'8, 10~8'8, 10 7*8. 
Parts 2, 3, and 4 were included to give adequate controls. While an 
ideal of 125 LD^ per mouse was aimed for, it was realized that the actual 
value would most likely be other than this; and therefore a titration 
would be necessary to determine the LD for the NT proper. From this 
the actual number of LD^ doses per mouse could be determined: 
125 x LDcq for wet pool 
#LD^q doses for NT =___^^ 
LD^q for NT 
= Dilution of wet pool virus used for NT 
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